

**MARKED COPY OF SUBSTITUTE SPECIFICATION**

## MULTIVALENT T CELL RECEPTOR COMPLEXES

The invention relates to T cell receptors (TCRs) in multivalent form and to their use in detecting cells which carry specific peptide antigens presented in the context of major histocompatibility complex (MHC) at their surface. The 5 invention further relates to delivery methods, in particular for the delivery of therapeutic agents, to target cells using the multimeric TCRs.

### General background

#### 1. Antigen presentation on the cell surface

MHC molecules are specialised protein complexes which present short 10 protein fragments, peptide antigens, for recognition on the cell surface by the cellular arm of the adaptive immune system.

Class I MHC is a dimeric protein complex consisting of a variable heavy chain and a constant light chain,  $\beta$ 2microglobulin. Class I MHC presents peptides which are processed intracellularly, loaded into a binding cleft in the MHC, 15 and transported to the cell surface where the complex is anchored in the membrane by the MHC heavy chain. Peptides are usually 8-11 amino acids in length, depending on the degree of arching introduced in the peptide when bound in the MHC. The binding cleft which is formed by the membrane distal  $\alpha$ 1 and  $\alpha$ 2 domains of the MHC heavy chain has "closed" ends, imposing quite 20 tight restrictions on the length of peptide which can be bound.

Class II MHC is also a dimeric protein consisting of an  $\alpha$  (heavy) and  $\beta$ (light) chain, both of which are variable glycoproteins and are anchored in the cell by transmembrane domains. Like Class I MHC, the Class II molecule forms a binding cleft in which longer peptides of 12-24 amino acids are inserted. 25 Peptides are taken up from the extracellular environment by endocytosis and processed before loading into the Class II complex which is then transported to the cell surface.

Each cell presents peptides in up to six different Class I molecules and a similar number of Class II molecules, the total number of MHC complexes presented being in the region of  $10^5$ - $10^6$  per cell. The diversity of peptides presented in Class I molecules is typically estimated to be between 1,000-  
5 10,000, with 90% of these being present in 100-1,000 copies per cell (Hunt,  
Michel *et al.*, 1992; Chicz, Urban *et al.*, 1993; Engelhard, Appella *et al.*, 1993;  
Huczko, Bodnar *et al.*, 1993). The most abundant peptides are thought to  
constitute between 0.4-5% of the total peptide presented which means that up  
to 20,000 identical complexes could be present on a single cell. An average  
10 number for the most abundant single peptide complexes is likely to be in the  
region of 2,000-4,000 per cell, and typical presentation levels of recognisable  
T cell epitopes are in the region of 100-500 complexes per cell (for review see  
(Engelhard, 1994)).

## **2. Recognition of antigen presenting cells**

15 A wide spectrum of cells can present antigen, as MHC-peptide, and the cells  
which have that property are known as antigen presenting cells (APCs). The  
type of cell which presents a particular antigen depends upon how and where  
the antigen first encounters cells of the immune system. APCs include the  
interdigitating dendritic cells found in the T cell areas of the lymph nodes and  
20 spleen in large numbers; Langerhan's cells in the skin; follicular dendritic cells  
in B cell areas of the lymphoid tissue; monocytes, macrophages and other  
cells of the monocyte/macrophage lineage; B cells and T cells; and a variety  
of other cells such as endothelial cells and fibroblasts which are not classical  
APCs but can act in the manner of an APC.

25 Antigen presenting cells are recognised by a subgroup of lymphocytes which  
mature in the thymus (T cells) where they undergo a selection procedure  
designed to ensure that T cells which respond to self-peptides are eradicated  
(negative selection). In addition, T cells which do not have the ability to

recognise the MHC variants which are presented (in man, the HLA haplotypes) fail to mature (positive selection).

Recognition of specific MHC-peptide complexes by T cells is mediated by the T cell receptor (TCR) which is a heterodimeric glycoprotein consisting of an

5  $\alpha\alpha$  and a  $\beta$  chain linked by a disulphide bond. Both of the chains are anchored in the membrane by a transmembrane domain and have a short cytoplasmic tail. In a recombination process similar to that observed for antibody genes, the TCR  $\alpha$  and  $\beta$  chain genes rearrange from Variable, Joining, Diversity and Constant elements creating enormous diversity in the  
10 extracellular antigen binding domains (10 $\beta$  to 10 $\beta$  different possibilities).  
TCRs also exist in a different form with  $\gamma$  and  $\delta$  chains, but these are only present on about 5% of T cells.

Antibodies and TCRs are the only two types of molecule which recognise antigens in a specific manner. Thus, the TCR is the only receptor specific for

15 particular peptide antigens presented in MHC, the alien peptide often being the only sign of an abnormality within a cell.

TCRs are expressed in enormous diversity, each TCR being specific for one or a few MHC-peptide complexes. Contacts between TCR and MHC-peptide ligands are extremely short-lived, usually with a half-life of less than 1 second.

20 Adhesion between T cells and target cells, presumably TCR/MHC-peptide, relies on the employment of multiple TCR/MHC-peptide contacts as well as a number of coreceptor-ligand contacts.

T cell recognition occurs when a T-cell and an antigen presenting cell (APC) are in direct physical contact and is initiated by ligation of antigen-specific

25 TCRs with pMHC complexes. The TCR is a heterodimeric cell surface protein of the immunoglobulin superfamily which is associated with invariant proteins of the CD3 complex involved in mediating signal transduction.

TCRs exist in ( $\alpha\beta$  and  $\gamma\delta$  forms, which are structurally similar but have quite

distinct anatomical locations and probably functions. The extracellular portion of the receptor consists of two membrane-proximal constant domains, and two membrane-distal variable domains bearing highly polymorphic loops analogous to the complementarity determining regions (CDRs) of antibodies.

5 It is these loops which form the MHC-binding site of the TCR molecule and determine peptide specificity. The MHC class I and class II ligands are also immunoglobulin superfamily proteins but are specialised for antigen presentation, with a highly polymorphic peptide binding site which enables them to present a diverse array of short peptide fragments at the APC cell 10 surface.

Recently, examples of these interactions have been characterised structurally (Garboczi, Ghosh *et al.* 1996; Garcia, Degano *et al.* 1996; Ding, Smith *et al.* 1998). Crystallographic structures of murine and human Class I pMHC-TCR

15 complexes indicate a diagonal orientation of the TCR over its pMHC ligand and show poor shape complementarity in the interface. CDR3 loops contact exclusively peptide residues. Comparisons of liganded and unliganded TCR structures also suggest that there is a degree of flexibility in the TCR CDR loops (Garboczi and Biddison 1999).

T cell activation models attempt to explain how such protein-protein 20 interactions at an interface between T cell and antigen presenting cell (APC) initiate responses such as killing of a virally infected target cell. The physical properties of TCR-pMHC interactions are included as critical parameters in many of these models. For instance, quantitative changes in TCR dissociation rates have been found to translate into qualitative differences in 25 the biological outcome of receptor engagement, such as full or partial T cell activation, or antagonism (Matsui, Boniface *et al.* 1994; Rabinowitz, Beeson *et al.* 1996; Davis, Boniface *et al.* 1998).

TCR-pMHC interactions have been shown to have low affinities and relatively slow kinetics. Many studies have used biosensor technology, such as

Biacore BIACORE™ (Willcox, Gao *et al.* 1999; Wyer, Willcox *et al.* 1999), which exploits surface plasmon resonance (SPR) and enables direct affinity and real-time kinetic measurements of protein-protein interactions (Garcia, Scott *et al.* 1996; Davis, Boniface *et al.* 1998). However, the receptors  
5 studied are either alloreactive TCRs or those which have been raised in response to an artificial immunogen.

### 3. TCR and CD8 interactions with MHC-peptide complexes

The vast majority of T cells restricted by (i.e. which recognise) Class I MHC-peptide complexes also require the engagement of the coreceptor CD8 for  
10 activation, while T cells restricted by Class II MHC require the engagement of CD4. The exact function of the coreceptors in T cell activation is not yet entirely clarified. Neither are the critical mechanisms and parameters controlling activation. However, both CD8 and CD4 have cytoplasmic domains which are associated with the kinase p56<sup>ck</sup> which is involved in the  
15 very earliest tyrosine phosphorylation events which characterise T cell activation. CD8 is dimeric receptor, expressed either in an  $\alpha\alpha$  form or, more commonly, in an  $\alpha\beta$  form. CD4 is a monomer. In the CD8 receptor only the  $\alpha$ - chain is associated with p56<sup>ck</sup>.

Recent determinations of the physical parameters controlling binding of TCR  
20 and CD8 to MHC, using soluble versions of the receptors, has shown that binding by TCR dominates the recognition event. TCR has significantly higher affinity for MHC than the coreceptors (Willcox, Gao *et al.*., Wyer, Willcox *et al.*.. 1999).

The individual interactions of the receptors with MHC are very short lived at  
25 physiological temperature, i.e. 37°C. An approximate figure for the half-life of a TCR/MHC-peptide interaction, measured with a human TCR specific for the influenza virus "matrix" peptide presented by HLA-A\*0201 (HLA-A2), is 0.7

seconds. The half-life of the CD8aa interaction with this MHC/peptide complex is less than 0.01 seconds or at least 18 times faster.

#### 4. Production of soluble MHC-peptide complexes

Soluble MHC-peptide complexes were first obtained by cleaving the molecules of the surface of antigen presenting cells with papain (Bjorkman, Strominger et al., 1985). Although this approach provided material for crystallisation, it has, for Class I molecules, in recent years been replaced by individual expression of heavy and light chain in *E.coli* followed by refolding in the presence of synthetic peptide (Garboczi, Hung et al., 1992; Garboczi, 10 Madden et al., 1994; Madden, Garboczi et al., 1993; Reid McAdam et al., 1996; Reid, Smith et al., 1996; Smith, Reid et al., 1996; Smith, Reid et al., 1996; Gao, Tormo et al., 1997; Gao, Gerth et al., 1998). This approach has several advantages over previous methods in that a better yield is obtained at a lower cost, peptide identity can be controlled very accurately, and the final 15 product is more homogeneous. Furthermore, expression of modified heavy or light chain, for instance fused to a protein tag, can be easily performed.

#### 5. MHC-peptide tetramers

The short half-life of the individual binding event between peptide-MHC and TCR and CD8 receptors makes this interaction unsuitable for use in the 20 development of detection methods. This problem has been overcome by a novel technique employing tetrameric molecules of peptide-MHC complexes (Altman et al., 1996). The higher avidity of the multimeric interaction provides a dramatically longer half-life for the molecules binding to a T cell than would be obtained with binding of a monomeric peptide-MHC complex. This 25 technique is also described in WO 96/26962.

The tetrameric peptide-MHC complex is made with synthetic peptide,  $\beta$ 2microglobulin (usually expressed in *E.coli*), and soluble MHC heavy chain (also expressed in *E.coli*). The MHC heavy chain is truncated at the start of

the transmembrane domain and the transmembrane domain is replaced with a protein tag constituting a recognition sequence for the bacterial modifying enzyme *Bir A* (Barker and Campbell, 1981; Barker and Campbell, 1981; Schatz, 1993). *Bir A* catalyses the biotinylation of a lysine residue in a somewhat redundant recognition sequence (Schatz, 1993), however, the specificity is high enough to ensure that the vast majority of protein will be biotinylated only on the specific position on the tag. The biotinylated protein can then be covalently linked to avidin, streptavidin or extravidin (Sigma) each of which has four binding sites for biotin, resulting in a tetrameric molecule of peptide-MHC complexes (Altman *et al.*, 1996).

## 6. MHC-peptide tetramers and staining of T cells

WO 96/26962 and Altman *et al.*, (1996) also describe a technology for staining T cells with a particular specificity using soluble MHC-peptide complexes, made as tetrameric molecules. This technology has gained scientific significance in the detection and quantification of T cells (Callan *et al.*, 1998; Dunbar *et al.*, 1998; McHeyzer Williams *et al.*, 1996; Murali Krishna *et al.*, 1998; Ogg *et al.*, 1998) and may hold potential in diagnostics (for review see (McMichael and O'Callaghan, 1998)). Although the half-life of the interaction between MHC with TCR and CD8, as measured with soluble proteins, is very short, i.e. less than a second, stable binding is achieved with the tetramer so that staining can be detected. This is due to a higher avidity of the multimeric interaction between the tetramer and the T cell.

## 7. Soluble TCR

Production of soluble TCR has only recently been described by a number of groups. In general, all methods describe truncated forms of TCR, containing either only extracellular domains or extracellular and cytoplasmic domains. Thus, in all cases, the transmembrane domains have been deleted from the expressed protein. Although many reports show that TCR produced

according to their methods can be recognised by TCR-specific antibodies (indicating that the part of the recombinant TCR recognised by the antibody has correctly folded), none has been able to produce a soluble TCR at a good yield which is stable at low concentrations and which can recognise MHC-peptide complexes.

The first approach to yield crystallisable material made use of expression in eukaryotic cells but the material is extremely expensive to produce (Garcia, Degano *et al.*, 1996; Garcia, Scott *et al.*, 1996). Another approach which has produced crystallisable material made use of an *E.coli* expression system 10 similar to what has previously been used for MHC-peptide complexes (Garboczi, Ghosh *et al.*, 1996; Garboczi, Utz *et al.*, 1996). The latter method, which involves expression of the extracellular portions of the TCR chains, truncated immediately before the cysteine residues involved in forming the interchain disulphide bridge, followed by refolding *in vitro* has turned out not 15 to be generally applicable. Most heterodimeric TCRs appear to be unstable when produced in this fashion due to low affinity between the  $\alpha$  and  $\beta$  chains.

In addition a number of other descriptions of engineered production of soluble TCR exist. Some of these describe only the expression of either the  $\alpha$  or  $\beta$  chain of the TCR, thus yielding protein which does not retain MHC-peptide 20 specific binding (Calaman, Carson *et al.*, 1993; Ishii, Nakano *et al.*, 1995).  $\beta$  chain crystals have been obtained without  $\alpha$  chain, either alone or bound to superantigen (Bentley, Boulot *et al.*, 1995; Boulot, Bentley *et al.*, 1994; Fields, Malchiodi *et al.*, 1996).

Other reports describe methods for expression of heterodimeric  $\gamma/\delta$  or  $\alpha/\beta$  25 TCR (Corr, Slanetz *et al.*, 1994; Eilat, Kikuchi *et al.*, 1992; Gregoire, Rebai *et al.*, 1996; Gregoire, Malissen *et al.*, 1991; Ishii, Nakano *et al.*, 1995; Necker, Rebai *et al.*, 1991; Romagne, Pyrat *et al.*, 1996; Weber, Traunecker *et al.*, 1992). In some cases, the TCR has been expressed as a single chain fusion protein (Broker, Peter *et al.*, 1993; Gregoire, Malissen *et al.*, 1996;

Schlueter, Schodin *et al.*, 1996). Another strategy has been to express the TCR chains as chimeric proteins fused to Ig hinge and constant domains (Eilat, Kikuchi *et al.*, 1992; Weber, Traunecker *et al.*, 1992). Other chimeric TCR proteins have been expressed with designed sequences which form 5 coiled-coils which have high affinity and specificity for each other, thus stabilising TCR  $\alpha$ - $\beta$  contacts and increasing solubility. This strategy has been reported to yield soluble TCR both from the *baculovirus* expression system and from *E.coli* (Chang, Bao *et al.*, 1994; Golden, Khandekar *et al.*, 1997).

A method for making soluble TCR which can recognise a TCR ligand is 10 described herein. According to a preferred embodiment of this method, extracellular fragments of TCR are expressed separately as fusions to the "leucine zippers" of c-jun and c-fos and then refolded *in vitro*. The TCR chains do not form an interchain disulphide bond as they are truncated just prior to the cysteine residue involved in forming that bond in native TCR. 15 Instead, the heterodimeric contacts of the  $\alpha$  and  $\beta$  chains are supported by the two leucine zipper fragments which mediate heterodimerisation in their native proteins.

## **8. Detection using TCR**

The peptide-specific recognition of antigen presenting cells by T cells is 20 based on the avidity obtained through multiple low-affinity receptor/ligand interactions. These involve TCR/MHC-peptide interactions and a number of coreceptor/ligand interactions. The CD4 and CD8 coreceptors of class II restricted and class I restricted T cells, respectively, also have the MHC, but not the peptide, as their ligand. However, the epitopes on the MHC with 25 which CD4 and CD8 interact do not overlap with the epitope which interacts with the TCR.

This recognition mechanism opens the possibility that peptide-specific recognition of antigen presenting cells can be mediated by soluble TCR in

such a way that the half-life of the contact could be of therapeutic use. It has not been clear, however, whether the stability obtained through the avidity of multiple TCR/MHC-peptide interactions in the absence of the support from coreceptors would be sufficient for such purposes. Staining of antigen

5 presenting cells by a soluble TCR was reported by Plaksin *et al.* (Plaksin *et al.*, 1997). This result was obtained with a so-called single-chain TCR, a single protein consisting of three of the four domains of the ( $\alpha$  and  $\beta$  chains from TCR. However, staining was performed by incubating antigen presenting cells with chemically modified TCR which was then crosslinked, an

10 approach which would not be practicable *in vivo*. Furthermore, the method only convincingly detected levels of peptide (incubation of antigen presenting cells with approximately 100 $\mu$ M peptide), which are far greater than the levels of peptide which would be presented *in vivo*.

The fact that specific staining of T cells can be accomplished with MHC-peptide tetramers (Altman *et al.*, 1996), the "reciprocal" situation, might be considered to lend some support to the idea that multimeric TCR would mediate relatively stable contact to a cell presenting the relevant peptide antigen on the surface. However, this is in fact not expected to be the case since there are three significant conditions which favour recognition of T cells

15 by multimeric MHC-peptide over recognition of antigen presenting cells by multimeric TCR:

- i) multimeric MHC-peptide complexes can form contacts to both TCR and CD4 or CD8 coreceptors on the T cell surface. Multimeric TCR depends on the TCR/MHC-peptide contact alone.
- 5 ii) the concentration of TCR on the T cell surface is significantly higher than the concentration of MHC-peptide on the surface of the antigen presenting cell (Engelhard, 1994).
- 10 iii) antigen presenting cells present a multitude of different MHC-peptide complexes on their surface (Engelhard, 1994) whereas a T cell normally will express only one  $\alpha/\beta$  or  $\gamma/\delta$  combination.

10 **9. Attachment of proteins to liposomes**

Liposomes are lipid vesicles made up of bilayers of lipid molecules enclosing an aqueous volume. The lipid bilayers are formed from membrane lipids, usually but not exclusively phospholipids. Phospholipid molecules exhibit amphipathic properties and therefore they are aggregated either in a 15 crystalline state or in polar solvents into ordered structures with typical lyotropic fluid crystalline symmetries. In aqueous solutions phospholipid molecules normally form self-closed spherical or oval structures where one or several phospholipid bilayers entrap part of the solvent in their interior.

20 Biologically active compounds entrapped in liposomes are protected from the external environment and diffuse out gradually to give a sustained effect.

Drug delivery by liposomes directed to specific locations by proteins on their surface has enormous therapeutic potential (Allen, 1997; Langer, 1998). In particular, slow release of a drug in a specific location increases the efficacy of the drug while allowing the overall amount that is administered to be 25 reduced. The use of liposomes for such applications is developing rapidly and a large amount of data is emerging for instance on their ability to circulate in the blood stream (Uster *et al.*, 1996) and their survival time (Zalipsky *et al.*.,

1996). A particularly useful feature may be that liposome carried drugs may be administered orally (Chen and Langer, 1997; Chen *et al.*, 1996; Okada *et al.*, 1995).

A number of reports describe the attachment of antibodies to liposomes  
5 (Ahmad and Allen, 1992; Ahmad *et al.*, 1993; Hansen *et al.*, 1995). US  
5,620,689 discloses so-called "immunoliposomes" in which antibody or  
antibody fragments effective to bind to a chosen antigen on a B lymphocyte or  
a T lymphocyte, are attached to the distal ends of the membrane lipids in  
liposomes having a surface coating of polyethylene glycol chains. However  
10 antibody-antigen interactions are usually quite high affinity and may not be  
suitable for multivalent targeting for that reason.

### **The Invention**

It is an aim of the present invention to provide a means for targeting a specific  
MHC-peptide complex.

15 It is a particular aim of the present invention to provide TCR in a form which  
enables the detection of specific MHC-peptide complexes, especially though  
not exclusively MHC-peptide complexes presented *in vivo*.

It is a further aim of the invention to provide a targeted delivery vehicle  
capable of delivering reagents, in particular therapeutic agents, to sites of  
20 expression of specific MHC-peptide complexes *in vivo*.

The inventors have now surprisingly found that TCR can be used very  
effectively for targeting purposes *in vivo* and have successfully devised a  
strategy for using TCR molecules for targeting purposes.

25 The invention provides in one aspect a synthetic multivalent T cell receptor  
(TCR) complex for binding to a MHC-peptide complex, which TCR complex  
comprises a plurality of T cell receptors specific for the MHC-peptide  
complex.

The invention is concerned primarily with  $\alpha\beta$  TCRs which are present on 95% of T cells.

In another aspect, the invention provides a multivalent TCR complex comprising or consisting of a multimerised recombinant T cell receptor

5 heterodimer having enhanced binding capability compared to a non-multimeric T cell receptor heterodimer. The multimeric T cell receptors may comprise two or more TCR heterodimers.

In another aspect, the invention provides a method for detecting MHC-peptide complexes which method comprises:

10 (i) providing (a) a synthetic multivalent T cell receptor complex comprising a plurality of T cell receptors, and/or (b) a multivalent T cell receptor complex comprising a multimerised recombinant T cell receptor heterodimer having enhanced binding capability compared to a non-multimeric T cell receptor heterodimer, said T cell receptors being

15 specific for the MHC-peptide complexes;

(ii) contacting the multivalent TCR complex with the MHC-peptide complexes; and

(iii) detecting binding of the multivalent TCR complex to the MHC-peptide complexes.

20 In yet another aspect the invention provides a method for delivering a therapeutic agent to a target cell, which method comprises:

(i) providing (a) a synthetic multivalent TCR complex comprising a plurality of T cell receptors, and/or (b) a multivalent TCR complex comprising a multimerised recombinant T cell receptor heterodimer having enhanced binding capability compared to a non-multimeric T cell receptor heterodimer, said T cell receptors being specific for the

25

MHC-peptide complexes and the multivalent TCR complex having the therapeutic agent associated therewith;

5 (ii) contacting the multivalent TCR complex with potential target cells under conditions to allow attachment of the T cell receptors to the target cell.

The multivalent TCR complexes (or multimeric binding moieties) according to the invention are useful in their own right for tracking or targeting cells presenting particular antigens *in vitro* or *in vivo*, and are also useful as intermediates for the production of further multivalent TCR complexes having 10 such uses. The multivalent TCR complex may therefore be provided in a pharmaceutically acceptable formulation for use *in vivo*.

In the context of the present invention, a multivalent TCR complex is "synthetic" if it cannot be found in, or is not native to, a living organism, for example if it is non-metabolic and/or has no nucleus. Thus, for example, it is 15 preferred if the TCRs are in the form of multimers, or are present in a lipid bilayer, for example, in a liposome. It is also possible that the TCR complex could be formed by isolating T cells and removing the intracellular components, i.e. so that the complex has no nucleus, for example. The resulting "ghost" T cell would then have simply the T cell membrane including 20 the T cell receptors. Such ghost T cells may be formed by lysing T cells with a detergent, separating the intracellular components from the membrane (by centrifugation for example) and then removing the detergent and reconstituting the membrane.

In its simplest form, a multivalent TCR complex according to the invention 25 comprises a multimer of two or three or four or more T cell receptor molecules associated (e.g. covalently or otherwise linked) with one another preferably via a linker molecule. Suitable linker molecules include multivalent attachment molecules such as avidin, streptavidin and extravidin, each of which has four binding sites for biotin. Thus, biotinylated TCR molecules can

be formed into multimers of T cell receptor having a plurality of TCR binding sites. The number of TCR molecules in the multimer will depend upon the quantity of TCR in relation to the quantity of linker molecule used to make the multimers, and also on the presence or absence of any other biotinylated

5 molecules. Preferred multimers are trimeric or tetrameric TCR complexes.

The multivalent TCR complexes for use in tracking or targeting cells expressing specific MHC-peptide complex are preferably structures which are a good deal larger than the TCR trimers or tetramers. Preferably the structures are in the range 10nm to 10μm in diameter. Each structure may

10 display multiple TCR molecules at a sufficient distance apart to enable two or more TCR molecules on the structure to bind simultaneously to two or more MHC-peptide complexes on a cell and thus increase the avidity of the multimeric binding moiety for the cell.

Suitable structures for use in the invention include membrane structures such

15 as liposomes and solid structures which are preferably particles such as beads, for example latex beads. Other structures which may be externally coated with T cell receptor molecules are also suitable. Preferably, the structures are coated with multimeric T cell receptor complexes rather than with individual T cell receptor molecules.

20 In the case of liposomes, the T cell receptor molecules may be attached to the outside of the membrane or they may be embedded within the membrane. In the latter case, T cell receptor molecules including part or all of the transmembrane domain may be used. In the former case, soluble T cell receptor molecules are preferred. A soluble form of a T cell receptor is

25 usually derived from the native form by deletion of the transmembrane domain. The protein may be truncated by removing both the cytoplasmic and the transmembrane domains, or there may be deletion of just the transmembrane domain with part or all of the cytoplasmic domain being retained. The protein may be modified to achieve the desired form by

proteolytic cleavage, or by expressing a genetically engineered truncated or partially deleted form.

Generally, the soluble T cell receptor will contain all four external domains of the molecule, that is the  $\alpha$  and  $\beta$  variable domains and the ( $\alpha$  and  $\beta$  constant domains. However, any soluble form of TCR which retains the MHC-peptide binding characteristics of the variable domains is envisaged. For example, it may be possible to omit one or other of the constant domains without significantly disturbing the binding site.

It is preferred if the multivalent TCR complex in accordance with the invention 10 comprises a multimerised recombinant T cell receptor heterodimer having enhanced binding capability compared to a non-multimeric T cell receptor heterodimer. The refolded recombinant T cell receptor may comprise:

- i) a recombinant T cell receptor  $\alpha$  or  $\gamma$  chain extracellular domain having a first heterologous C-terminal dimerisation peptide; and
- 15 ii) a recombinant T cell receptor  $\beta$  or  $\delta$  chain extracellular domain having a second C-terminal dimerisation peptide which is specifically heterodimerised with the first dimerisation peptide to form a heterodimerisation domain.

Such a recombinant TCR may be for recognising Class I MHC-peptide 20 complexes and Class II MHC-peptide complexes.

The heterodimerisation domain of the recombinant TCR is preferably a so-called "coiled coil" or "leucine zipper". These terms are used to describe pairs of helical peptides which interact with each other in a specific fashion to form a heterodimer. The interaction occurs because there are complementary 25 hydrophobic residues along one side of each zipper peptide. The nature of the peptides is such that the formation of heterodimers is very much more favourable than the formation of homodimers of the helices. Leucine zippers

may be synthetic or naturally occurring. Synthetic leucines can be designed to have a much higher binding affinity than naturally occurring leucine zippers, which is not necessarily an advantage. In fact, preferred leucine zippers for use in the invention are naturally occurring leucine zippers or leucine zippers with a similar binding affinity. Leucine zippers from the c-jun and c-fos protein are an example of leucine zippers with a suitable binding affinity. Other suitable leucine zippers include those from the myc and max proteins (Amati, Dalton, *et al.* 1992). Other leucine zippers with suitable properties could easily be designed (O'Shea *et al.* 1993).

10 It is preferred that the soluble TCRs in the multimeric binding moieties in accordance with the invention have approximately 40 amino acid leucine zipper fusions corresponding to the heterodimerisation domains from c-jun (αchain) and c-fos (βchain) (O'Shea, Rutkowski *et al.* 1989, O'Shea, Rutkowski *et al.*, 1992, Glover and Harrison, 1995). Longer leucine zippers 15 may be used. Since heterodimerisation specificity appears to be retained even in quite short fragments of some leucine zipper domains, (O'Shea, Rutkowski *et al.*, 1992), it is possible that a similar benefit could be obtained with shorter c-jun and c-fos fragments. Such shorter fragments could have as few as 8 amino acids for example. Thus, the leucine zipper domains may be 20 in the range of 8 to 60 amino acids long.

The molecular principles of specificity in leucine zipper pairing is well characterised (Landschulz, Johnson *et al.*, 1988; McKnight, 1991) and leucine zippers can be designed and engineered by those skilled in the art to form homodimers, heterodimers or trimeric complexes (Lumb and Kim, 1995; 25 Nautiyal, Woolfson *et al.*, 1995; Boice, Dieckmann *et al.*, 1996, Chao, Houston *et al.*, 1996). Designed leucine zippers, or other heterodimerisation domains, of higher affinity than the c-jun and c-fos leucine zippers may be beneficial for the expression of soluble TCRs in some systems. However, as mentioned in more detail below, when soluble TCR is folded *in vitro*, a 30 solubilising agent is preferably included in the folding buffer to reduce the

formation of unproductive protein aggregates. One interpretation of this phenomenon is that the kinetics of folding of the leucine zipper domains are faster than for the TCR chains, leading to dimerisation of unfolded TCR  $\alpha$  and  $\beta$  chain, in turn causing protein aggregation. By slowing the folding process

5 and inhibiting aggregation by inclusion of solubilising agent, the protein can be maintained in solution until folding of both fusion domains is completed. Therefore, heterodimerisation domains of higher affinity than the c-fos and c-jun leucine zippers may require higher concentrations of solubilising agent to achieve a yield of soluble TCRs comparable to that for c-jun and c-fos.

10 Different biological systems use a variety of methods to form stable homo- and hetero- protein dimers, and each of these methods in principle provide an option for engineering dimerisation domains into genetically modified proteins. Leucine zippers (Kouzarides and Ziff 1989) are probably the most popular dimerisation modules and have been widely used for production of genetically

15 designed dimeric proteins. Thus, the leucine zipper of GCN4, a transcriptional activator protein from the yeast *Saccharomyces cerevisiae*, has been used to direct homodimerisation of a number of heterologous proteins (Hu, Newell *et al.* 1993; Greenfield, Montelione *et al.* 1998). The preferred strategy therefore is to use zippers that direct formation of

20 heterodimeric complexes such as the Jun/Fos leucine zipper pair (de Kruif and Logtenberg 1996; Riley, Ralston *et al.* 1996).

The heterodimerisation domain is not limited to leucine zippers. Thus, it may be provided by disulphide bridge-forming elements. Alternatively, it may be provided by the SH3 domains and hydrophobic/proline rich counterdomains,

25 which are responsible for the protein-protein interactions seen among proteins involved in signal transduction (reviewed by Schlessinger, (Schlessinger 1994). Other natural protein-protein interactions found among proteins participating in signal transduction cascades rely on associations between post-translationally modified amino acids and protein modules that

30 specifically recognise such modified residues. Such post-translationally

modified amino acids and protein modules may form the heterodimerisation domain. An example of a protein pair of this type is provided by tyrosine phosphorylated receptors such as Epidermal Growth Factor Receptor or Platelet Derived Growth Factor Receptor and the SH2 domain of GRB2

5 (Lowenstein, Daly *et al.* 1992; Buday and Downward 1993). As in all fields of science, new dimerisation modules are being actively sought (Chevray and Nathans 1992) and methods for engineering completely artificial modules have now successfully been developed (Zhang, Murphy *et al.* 1999).

In a preferred recombinant TCR, an interchain disulphide bond which forms

10 between two cysteine residues in the native  $\alpha$  and  $\beta$  TCR chains and between the native  $\gamma$  and  $\delta$  TCR chains, is absent. This may be achieved for example by fusing the dimerisation domains to the TCR receptor chains above the cysteine residues so that these residues are excluded from the recombinant protein. In an alternative example, one or more of the cysteine residues is  
15 replaced by another amino acid residue which is not involved in disulphide bond formation. These cysteine residues may not be incorporated because they may be detrimental to *in vitro* folding of functional TCR.

Refolding of the  $\alpha$  and  $\beta$  chains or  $\gamma$  and  $\delta$  chains of the preferred refolded

recombinant TCR of the multivalent TCR complex according to the invention

20 takes place *in vitro* under suitable refolding conditions. In a particular embodiment, a recombinant TCR with correct conformation is achieved by refolding solubilised TCR chains in a refolding buffer comprising a solubilising agent, for example urea. Advantageously, the urea may be present at a concentration of at least 0.1M or at least 1M or at least 2.5M, or about 5M.

25 An alternative solubilising agent which may be used is guanidine, at a concentration of between 0.1M and 8M, preferably at least 1M or at least 2.5M. Prior to refolding, a reducing agent is preferably employed to ensure complete reduction of cysteine residues. Further denaturing agents such as DTT and guanidine may be used as necessary. Different denaturants and  
30 reducing agents may be used prior to the refolding step (e.g. urea,  $\beta$ -

mercaptoethanol). Alternative redox couples may be used during refolding, such as a cystamine/cysteamine redox couple, DTT or  $\beta$ -mercaptoethanol/atmospheric oxygen, and cysteine in reduced and oxidised forms.

- 5     Preferably, the recombinant TCR chains have a flexible linker located between the TCR domain and the dimerisation peptide. Suitable flexible linkers include standard peptide linkers containing glycine, for example linkers containing glycine and serine. C-terminal truncations close to the cysteine residues forming the interchain disulphide bond are believed to be
- 10    advantageous because the  $\alpha$  and  $\beta$  chains are in close proximity through these residues in cellular TCRs. Therefore only relatively short linker sequences may be required to supply a nondistortive transition from the TCR chains to the heterodimerisation domain. It is preferred that the linker sequences Pro-Gly-Gly or Gly-Gly are used. However, the linker sequence
- 15    could be varied. For instance, the linker could be omitted completely, or reduced to a single residue, the preferred choice in this case being a single Glycine residue. Longer linkers variations are also likely to be tolerated in the soluble TCR, provided that they could be protected from protease attack which would lead to segregation of the dimerisation peptides from the
- 20    extracellular domains of the TCR with ensuing loss of  $\alpha$ - $\beta$  chain stability.

The soluble recombinant TCR is not necessarily  $\alpha$ - $\beta$ TCR. Molecules such as  $\gamma$ - $\delta$ ,  $\alpha$ - $\delta$  and  $\gamma$ - $\beta$ TCR molecules, as well as TCR molecules containing invariant alpha chains (pre-TCR) which are only expressed early in development are also included. Pre-TCR specifies the cell lineage which will express  $\alpha$ - $\beta$  T cell receptor, as opposed to those cells which will express  $\gamma$ - $\delta$  T cell receptor (for reviews, see (Aifantis, Azogui *et al.* 1998; von Boehmer, Aifantis *et al.* 1998; Wurch, Biro *et al.* 1998)). The Pre-TCR is expressed with the TCR  $\beta$  chain pairing with an invariant Pre-TCR  $\alpha$ chain (Saint Ruf, Ungewiss *et al.* 1994; Wilson and MacDonald 1995) which appears to commit

the cell to the  $\alpha$ - $\beta$  T cell lineage. The role of the Pre-TCR is therefore thought to be important during thymus development (Ramiro, Trigueros *et al.* 1996).

Standard modifications to the recombinant TCR may be made as appropriate. These include for example altering an unpaired cysteine residue in the 5 constant region of the  $\beta$  chain to avoid incorrect intrachain or interchain pairing.

The signal peptide may be omitted since it does not serve any purpose in the mature receptor or for its ligand binding ability, and may in fact prevent the TCR from being able to recognise ligand. In most cases, the cleavage site at 10 which the signal peptide is removed from the mature TCR chains is predicted but not experimentally determined. Engineering the expressed TCR chains such that they are a few, e.g. up to about 10 for example, amino acids longer or shorter at the N-terminal end will have no significance for the functionality of the soluble TCR. Certain additions which are not present in the original 15 protein sequence could be added. For example, a short tag sequence which can aid in purification of the TCR chains could be added provided that it does not interfere with the correct structure and folding of the antigen binding site of the TCR.

For expression in *E.coli*, a methionine residue may be engineered onto the N- 20 terminal starting point of the predicted mature protein sequence in order to enable initiation of translation.

Far from all residues in the variable domains of TCR chains are essential for antigen specificity and functionality. Thus, a significant number of mutations can be introduced in this region without affecting antigen specificity and 25 functionality.

By contrast, certain residues involved in forming contacts to the peptide antigen or the HLA heavy chain polypeptide, i.e. the residues constituting the CDR regions of the TCR chains, may be substituted for residues that would

enhance the affinity of the TCR for the ligand. Such substitutions, given the low affinity of most TCRs for peptide-MHC ligands, could be useful for enhancing the specificity and functional potential of soluble TCRs. In the examples herein, the affinities of soluble TCRs for peptide-MHC ligands are

5 determined. Such measurements can be used to assay the effects of mutations introduced in the TCR and thus also for the identification of TCRs containing substitutions which enhance the activity of the TCR.

Far from all residues in the constant domains of TCR chains are essential for antigen specificity and functionality. Thus, a significant number of mutations

10 can be introduced in this region affecting antigen specificity.

In Example 17 below, we have shown that two amino acid substitutions in the constant domain of a TCR  $\beta$  chain had no detectable consequences for the ability of the TCR to bind a HLA-peptide ligand.

The TCR  $\beta$  chain contains a cysteine residue which is unpaired in the cellular or native TCR. Mutation of this residue enhances the efficiency of *in vitro* refolding of soluble TCR. Substitutions of this cysteine residue for serine or alanine has a significant positive effect on refolding efficiencies *in vitro*.

Similar positive effects, or even better effects, may be obtained with substitutions for other amino acids.

20 As mentioned previously, it is preferred that the cysteine residues forming the interchain disulphide bond in native TCR are not present so as to avoid refolding problems. However, since the alignment of these cysteine residues is the natural design in the TCR and also has been shown to be functional with this alignment for the *c-jun* and *c-fos* leucine zipper domains (O'Shea *et* 25 *al.*, 1989), these cysteine residues could be included provided that the TCR could be refolded.

Because the constant domains are not directly involved in contacts with the peptide-MHC ligands, the C-terminal truncation point may be altered

substantially without loss of functionality. For instance, it should be possible to produce functional soluble TCRs excluding the entire constant domain. In principle, it would be simpler to express and fold soluble TCRs comprising only the variable regions or the variable regions and only a short fragment of 5 the constant regions, because the polypeptides would be shorter. However, this strategy is not preferred. This is because the provision of additional stability of the  $\alpha$ - $\beta$  chain pairing through a heterodimerisation domain would be complicated because the engineered C-termini of the two chains would be some distance apart, necessitating long linker sequences. The advantage of 10 fusing heterodimerisation domains just prior to the position of the cysteines forming the interchain disulphide bond, as is preferred, is that the ( $\alpha$  and  $\beta$  chains are held in close proximity in the cellular receptor. Therefore, fusion at this point is less likely to impose distortion on the TCR structure.

It is possible that functional soluble TCR could be produced with a larger 15 fragment of the constant domains present than is preferred herein, i.e. they constant domains need not be truncated just prior to the cysteines forming the interchain disulphide bond. For instance, the entire constant domain except the transmembrane domain could be included. It would be advantageous in this case to mutate the cysteine residues forming the interchain disulphide 20 bond in the cellular TCR.

In addition to aiding interchain stability through a heterodimerisation domain, incorporation of cysteine residues which could form an interchain disulphide bond could be used. One possibility would be to truncate the  $\alpha$  and  $\beta$  chains close to the cysteine residues forming the interchain disulphide bond without 25 removing these so that normal disulphide bonding could take place. Another possibility would be to delete only the transmembrane domains of the ( $\alpha$  and  $\beta$  chains. If shorter fragments of the  $\alpha$  and  $\beta$  chains were expressed, cysteine residues could be engineered in as substitutions at amino acid positions where the folding of the two chains would bring the residues in close 30 proximity, suitable for disulphide bond formation.

Purification of the TCR may be achieved by many different means.

Alternative modes of ion exchange may be employed or other modes of protein purification may be used such as gel filtration chromatography or affinity chromatography.

- 5 In the method of producing a recombinant TCR, folding efficiency may also be increased by the addition of certain other protein components, for example chaperone proteins, to the refolding mixture. Improved refolding has been achieved by passing protein through columns with immobilised mini-chaperones (Altamirano, Golbik *et al.* 1997; Altamirano, Garcia *et al.* 1999).
- 10 In addition to the methods described in the examples, alternative means of biotinyling the TCR may be possible. For example, chemical biotinylation may be used. Alternative biotinylation tags may be used, although certain amino acids in the biotin tag sequence are essential (Schatz *et al.* 1993). The mixture used for biotinylation may also be varied. The enzyme requires Mg-ATP and low ionic strength although both of these conditions may be varied e.g. it may be possible to use a higher ionic strength and a longer reaction time. It may be possible to use a molecule other than avidin or streptavidin to form multimers of the TCR. Any molecule which binds biotin in a multivalent manner would be suitable. Alternatively, an entirely different linkage could be devised (such as poly-histidine tag to chelated nickel ion (Qiagen Product Guide 1999, Chapter 3 "Protein Expression, Purification, Detection and Assay" p. 35-37). Preferably, the tag is located towards the C-terminus of the protein so as to minimise the amount of steric hindrance in the interaction with potential peptide-MHC complexes.
- 15 20 25 To enable detection of the multivalent TCR complex, for example for diagnostic purposes, a detectable label may be included. A suitable label may be chosen from a variety of known detectable labels. The types of label which are suitable include fluorescent, photoactivatable, enzymatic, epitope, magnetic and particle (e.g. gold) labels. Particularly suitable for *in vitro* use

are fluorescent labels such as FITC. Particularly suitable for *in vivo* use are labels which are suitable for external imaging after administration to a mammal, such as a radionuclide which emits radiation that can penetrate soft tissue. The label may be attached to or incorporated into the multivalent TCR

5 complex at any suitable site. In the case of liposomes, it may be attached to or incorporated into the membrane, or entrapped inside the membrane. In the case of particles or beads the label may be located in the particle or bead itself, or attached to the outside for example in the T cell receptor molecules. Conveniently, the label is attached to a multivalent linker molecule from which

10 T cell receptor complexes are formed. In tetrameric TCR formed using biotinylated heterodimers, fluorescent streptavidin (commercially available) can be used to provide a detectable label. A fluorescently labelled tetramer will be suitable for use in FACS analysis, for example to detect antigen presenting cells carrying the peptide for which the TCR is specific.

15 Another manner in which the multivalent TCR complexes may be detected is by the use of TCR-specific antibodies, in particular monoclonal antibodies. There are many commercially available anti-TCR antibodies, such as  $\beta$ FI and  $\alpha$ FI, which recognise the constant regions of the  $\beta$  and  $\alpha$  chain, respectively.

For therapeutic applications, a therapeutic agent is attached to or

20 incorporated into the multivalent TCR complex according to the invention. In a preferred embodiment, the multivalent TCR complex for therapeutic use is a liposome coated with T cell receptors, the therapeutic agent being entrapped within the liposome. The specificity of the T cell receptors enables the localisation of the liposome-contained drugs to the desired target site such as

25 a tumour or virus-infected cell. This would be useful in many situations and in particular against tumours because not all cells in the tumour present antigens and therefore not all tumour cells are detected by the immune system. With multivalent TCR complex, a compound could be delivered such that it would exercise its effect locally but not only on the cell it binds to.

30 Thus, one particular strategy envisages anti-tumour molecules associated

with or linked to multivalent TCR complexes comprising T cell receptors specific for tumour antigens.

The therapeutic agent may be for example a toxic moiety for example for use in cell killing, or an immunostimulating agent such as an interleukin or a 5 cytokine. Many toxins could be employed for this use, for instance radioactive compounds, enzymes (perforin for example) or chemotherapeutic agents (cis-platin for example).

One example of multivalent TCR complex in accordance with the invention is a tetramer containing three TCR molecules and one peroxidase molecule.

10 This could be achieved by mixing the TCR and the enzyme at a molar ratio of 3:1 to generate tetrameric complexes and isolating the desired multimer from any complexes not containing the correct ratio of molecules. Mixed molecules could contain any combination of molecules, provided that steric hindrance does not compromise or does not significantly compromise the 15 desired function of the molecules. The positioning of the binding sites on the streptavidin molecule is suitable for mixed tetramers since steric hindrance is not likely to occur.

Although it is an aim of the invention to provide multivalent TCR complexes having a plurality of T cell receptors of identical specificity, the possibility of 20 there also being present T cell receptors of a different specificity is not excluded. Indeed, there may be advantages in having two or more different specificities of T cell receptor, such as the possibility of targeting two or more different MHC-peptide complexes at one time. That can be useful for example to ensure detection of a target antigen in different individuals having 25 different HLA types, since an identical foreign antigen may be differently processed and presented according to the HLA type.

Similarly, the inclusion of molecules which have a binding activity different to that of the T cell receptor is also envisaged. Such molecules may improve targeting ability, or perform a useful function once the multivalent TCR

complex has reached its target. Examples of useful accessory molecules include CD8 to support the recognition of MHC-peptide complexes by the T cell receptor, and receptors with an immunomodulatory effect.

Examples of suitable MHC-peptide targets for the multivalent TCR complex

5 according to the invention include but are not limited to viral epitopes such as HTLV-1 epitopes (e.g. the Tax peptide restricted by HLA-A2; HTLV-1 is associated with leukaemia), HIV epitopes, EBV epitopes, CIVIV epitopes; melanoma epitopes and other cancer-specific epitopes; and epitopes associated with autoimmune disorders for example Rheumatoid Arthritis.

10 In more detail, T cell receptor-coated liposomes according to the invention (which can also be described as "artificial T cells") may be constructed as follows.

#### **Production of "artificial T cells"**

A number of methods exist for the production of liposomes. In the simplest

15 method, dry phospholipid films are deposited in a round-bottomed flask in excess solvent under gentle or vigorous shaking (Bangham *et al.*, 1965). Other methods include the sonication of multi-lamellar vesicles (MLVs) (Huang, 1969), by forcing a suspension of MLVs through a French Press (Barenholzt *et al.*, 1979), or by detergent solubilisation of lipids. Detergent

20 can be removed by dialysis, chromatography, adsorption, ultrafiltration or centrifugation (Brunner *et al.*, 1976).

 A number of techniques have been described for linking proteins to the surface of liposomes, usually through modified lipids. One such method uses biotinylated lipids. Herein is described a method for producing biotinylated T

25 cell receptor which can be linked to the biotinylated lipid via, for instance, avidin, streptavidin or extravidin. Another coupling method uses poly ethylene glycol (PEG) for the attachment of antibodies to liposomes (Hansen *et al.*, 1995) and the use of S-succinimidyl-S-thioacetate (SATA) has also been described (Konigsberg *et al.*, 1998).

These techniques produce small unilamellar vesicles with sizes ranging from 20-100 nm. Due to stability problems and in order to allow the entrapment of a wider range of materials preparation methods for larger unilamellar vesicles have been developed. These include dehydration-rehydration liposomes

5 (Tan and Gregoriadis, 1990), vesicles made by reverse phase evaporation (Szoka and Papahadjopoulos, 1978), or extrusion with freeze-thawing (Mayer *et al.*, 1985). With these methods encapsulation efficiencies of up to 65-80% can be achieved.

When initially discovered, liposomes were unstable but in recent years such

10 problems have been overcome by the use of more sophisticated forms of lipids and derivatised lipids (see (Allen, 1994) for review). Packaging of drugs, for instance, doxorubicin (Ahmad and Allen, 1992; Ahmad *et al.*, 1993), protein/antigens (Cohen *et al.*, 1994; Cohen *et al.*, 1991), or insulin (Edelman *et al.*, 1996) can be considered established technology.

15 **Advantages of liposome-linked TCR multimers**

The general advantages to this technology can be summarised in the following points:

- liposomes are cheap, easy to produce, easy to load using standard technology, and easy to load with a multitude of therapeutic

20 compounds. Reagents for making liposomes, including biotinylated lipids, are readily available, for instance from Avanti Polar Lipids Inc., USA.

- liposomes and proteins are biodegradable.
- TCR and lipids are non-immunogenic, therefore unlikely to evoke

25 secondary immune responses.

**Advantages to "artificial T cells"**

In their ability to track antigen presenting cells and their use for this purpose, and for transporting compounds to such cells, liposome-linked TCR and liposome-linked TCR multimers are predicted to have a number of advantages over TCR tetramers. These can be summarised in the following 5 points:

- free lateral movement of liposome-linked TCR prevents any steric hindrance which may hinder TCR/MHC-peptide contacts. In effect, the lateral mobility of TCRs linked to lipids in a liposome will be reminiscent of its ability to move in the T cell membrane.
- 10 - the flexibility in the surface of the liposome is reminiscent of the flexibility of the membrane of the real cell, potentially allowing a better contact surface than could be obtained with a tetramer or other simple complex.
- a high number of TCRs can be linked to a liposome, therefore high 15 avidity binding can be ensured. With TCR tetramers, binding will depend on sufficient avidity being obtained by a maximum of four TCR/MHC-peptide contacts.
- for both *in vivo* and *in vitro* use the liposome-linked TCR is less likely to 20 lose functionality through degradation of TCR, because of the far higher number of TCRs which can be linked to liposome than is the case with a tetramer or other simple TCR complex.
- the concentration of TCR on lipids can be controlled by mixing 25 biotinylated and non-biotinylated lipids in varying ratios. Similarly, lipids with other modifications which make them useful for binding protein, for instance, PEG-derivatised (Allen *et al.*, 1995; Hansen *et al.*, 1995) or SATA-derivatised (Konigsberg *et al.*, 1998) lipids can be mixed in varying ratios. This allows the strength of interaction to the

antigen presenting cell to be adapted to TCRs with different affinity or to the dominance of the peptide epitope on the antigen presenting cell.

- the potential for linking high numbers of molecules to the liposome opens the possibility for creating liposomes with multivalent MHC-peptide specificity by using more than one TCR. For instance, it could be envisaged that two or more TCRs specific for different epitopes associated with the same disease would be linked on a liposome giving this multiple specificities with which to detect cells that are disease-affected.

5 10 - similarly, the TCR could be mixed with other molecules or proteins which would exercise other desired functions in the vicinity of antigen presenting cells. For instance, cytokines or cytokine receptors, specific antibodies, superantigens, coreceptors like CD2, CD4, CD8 or CD28, or peptides may have properties which would be useful in this context.

15 This application can have very broad potential for localising reagents in proximity to certain antigen presenting cells.

**Examples of drugs and diseases which can be targeted with multivalent TCR complexes.**

A multitude of disease treatments can potentially be enhanced by localising 20 the drug through the specificity of multivalent TCR complexes, in particular the use of liposome-linked TCR will be useful.

Viral diseases for which drugs exist, e.g. HIV, SIV, EBV, CMV, would benefit from the drug being released in the near vicinity of infected cells. For cancer, the localisation in the vicinity of tumours or metastasis would enhance the 25 effect of toxins or immunostimulants. In autoimmune diseases immunosuppressive drugs could be released slowly, having more local effect over a longer time-span while minimally affecting the overall immuno-capacity. In the prevention of graft rejection, the effect of immunosuppressive drugs could be optimised in the same way. For vaccine delivery, the vaccine

antigen could be localised in the vicinity of professional antigen presenting cells, thus enhancing the efficacy of the antigen. The method can also be applied for imaging purposes.

Preferred features of each aspect of the invention are as for each of the other

5 aspects *mutatis mutandis*. The prior art documents mentioned herein are incorporated to the fullest extent permitted by law.

The invention is further described in the following examples, which do not limit the scope of the invention in any way.

Reference is made in the following to the accompanying drawings in which:

10 Figure 1 is a schematic view of a T-cell Receptor-leucine zipper fusion protein. Each chain consists of two immunoglobulin superfamily domains, one variable (V) and one constant (C). The constant domains are truncated immediately n-terminal of the interchain cysteine residues, and fused to a leucine zipper heterodimerisation motif from c-Jun ( $\alpha$ ) or c-Fos ( $\beta$ ) of around

15 40 amino acids at the C-terminal via a short linker. The ( $\alpha$ -Jun and  $\beta$ -Fos each contain two intrachain disulphide bonds and pair solely by non-covalent contacts. The alpha chain is shorter than the beta chain due to a smaller constant domain.

Figure 2 is a photograph of a reducing/non-reducing gel analysis of

20 heterodimeric JM22zip receptor. Identical samples of purified TCR-zipper were loaded onto a 15% acrylamide SDS gel, either under reducing conditions (lane 2) and non-reducing conditions (lane 4). Marker proteins are shown in lanes 1 and 3. Molecular weights are shown in kilodaltons. Under both sets of conditions, the non-covalently associated heterodimer is

25 dissociated into alpha and beta chains. In lane 4, each chain runs with a higher mobility and as a single band, indicating a single species of intra-chain disulphide bonding is present. This is compatible with correct disulphide bond formation.

Figure 3 is a graph showing the specific binding of JM22zip TCR to HLA-A2 Flu matrix (M58-66) complexes. HLA-A2 complexes, refolded around single peptides and biotinylated on  $\beta$ 2-microglobulin have been immobilised onto three streptavidin-coated flow cells: 3770 Resonance Units (RU) of HLA-A2

5 POL control onto flow cell (FC) 3, and two different levels of HLA-A2 M58-66 FLU (2970 RU on FC1 and 4960 RU on FC2). JM22zip has been injected in the soluble phase sequentially over all three flow cells at a concentration of 43gM for 60 seconds. During the injection, an above-background increase in the response of both HLA-A2 FLU-coated flow cells is seen, with

10 approximately 1000 RU and 700 RU of specific binding of JM22zip to flow cells 1 and 2 respectively

Figure 4 shows the protein sequence (one-letter code, top) and DNA sequence (bottom) of the soluble, HLA-A2/flu matrix restricted TCR  $\alpha$  chain from JM22, as fused to the "leucine zipper" domain of c-jun. Mutations

15 introduced in the 5' end of the DNA sequence to enhance expression of the gene in *E.coli* are indicated in small letters as is the linker sequence between the TCR and c-jun sequences.

Figure 5 shows the protein sequence (one-letter code, top) and DNA sequence (bottom) of the soluble, HLA-A2/flu matrix restricted TCR beta

20 chain from JM22, as fused to the "leucine zipper" domain of c-fos. The linker sequence between the TCR and c-fos sequences is indicated in small letters. Mutation of the DNA sequence which substitutes a serine residue for a cysteine residue is indicated in bold and underlined. This mutation increases the folding efficiency of the TCR.

25 Figure 6 shows the protein sequence (one-letter code, top) and DNA sequence (bottom) of the soluble, HLA-A2/flu matrix restricted TCR beta chain from JM22, as fused to the "leucine zipper" domain of c-fos and the biotinylation tag which acts as a substrate for BirA. The linker sequence between the TCR and c-fos sequences, and between c-fos and the

biotinylation tag, are indicated in small letters. Mutation of the DNA sequence which substitutes a Serine residue for a Cysteine residue is indicated in bold and underlined. This mutation increases the folding efficiency of the TCR.

Figure 7 is a schematic diagram of TCR-zipper-biotinylation tag fusion

5 protein.

Figure 8 shows the results of elution of refolded TCR from POROSPOROS™ 1-OHQ column with a gradient of sodium chloride. TCR elutes as a single peak at approximately 100 mM NaCl. Fractions containing protein with an OD(280 nm) of more than 0.1 were pooled and concentrated for biotinylation.

10 Figure 9 shows the results of separation of biotinylated TCR from free biotin by gel filtration on a SuperdexSUPERDEX™ 200HR 10/30 column (Pharmacia). TCR-biotin elutes at around 15 ml, corresponding to a molecular weight of 69 kDa. (Standard proteins and their elution volumes: Thyroglobulin (669 kDa) 10.14 ml, Apoferritin (443 kDa) 11.36 ml, beta-

15 amylase (200 kDa) 12.72 ml, BSA dimer (134 kDa) 13.12 ml, BSA monomer (67 kDa) 14.93 ml, ovalbumin (43 kDa) 15.00 ml, chymotrypsinogen A (25 kDa) 18.09 ml, RNase A (13.7 kDa) 18.91 ml)

Figure 10 shows the results of gel filtration of TCR tetramers on a

SuperdexSUPERDEX™ 200HR 10/30 column. Peaks at 14.61 and 12.74

20 correspond to BSA (monomer and dimer) used to stabilise extravidin. The peak at 11.59 contains TCR tetramers as judged by the presence of yellow FITC when extravidin-FITC is used to tetramerise. This peak corresponds to a molecular weight of 340 kDa, consistent with an extravidin-linked TCR tetramer.

25 Figure 11 shows the protein sequence (one-letter code, top) and DNA sequence (bottom) of the soluble, HTLV-1 Tax/HLA-A2 restricted TCR  $\alpha$  chain from clone A6 (Garboczi et al., 1996; Garboczi et al., 1996), as fused to the "leucine zipper" domain of c-jun. Mutations introduced in the 5' end of the

DNA sequence to enhance expression of the gene in E.coli are indicated in small letters as is the linker sequence between the TCR and c-jun sequences.

Figure 12 shows the protein sequence (one-letter code, top) and DNA sequence (bottom) of the soluble, HTLV-1 Tax/HLA-A2 restricted TCR beta chain from clone A6 (Garboczi et al., 1996; Garboczi et al., 1996), as fused to the "leucine zipper" domain of c-fos and the biotinylation tag which acts as a substrate for BirA. The linker sequence between the TCR and c-fos sequences is indicated in small letters. Mutation of the DNA sequence which substitutes an Alanine residue for a Cysteine residue is indicated in bold and underlined.

Figure 13 shows the protein sequence (one-letter code, top) and DNA sequence (bottom) of the soluble, HTLV-1 Tax/HLA-A2 restricted TCR  $\alpha$  chain from clone M1OB7/D3 (Ding et al., 1998), as fused to the "leucine zipper" domain of c-jun. The linker sequence between the TCR and c-jun sequences is indicated in small letters.

Figure 14 shows the protein sequence (one-letter code, top) and DNA sequence (bottom) of the soluble, HTLV-1 Tax/HLA-A2 restricted TCR beta chain from clone m1OB7/D3 (Ding et al., 1998), as fused to the "leucine zipper" domain of c-fos and the biotinylation tag which acts as a substrate for BirA. The linker sequence between the TCR and c-fos sequences is indicated in small letters. Mutation of the DNA sequence which substitutes an Alanine residue for a Cysteine residue is indicated in bold and underlined. Two silent mutations (P-G codons) introduced for cloning purposes and to remove a XmaI restriction site are also indicated in small letters.

Figure 15 shows the sequences of synthetic DNA primers used for "anchor amplification of TCR genes. Recognition sites for DNA restriction enzymes used for cloning are underlined. A: poly-C "anchor primer". B: TCR  $\alpha$  chain constant region specific primer. C: TCR  $\beta$  chain constant region specific primer.

Figure 16 shows the sequences of synthetic DNA primers used for PCR amplification of DNA fragments encoding the 40 amino acid coiled-coil ("leucine zipper") regions of c-jun and c-fos. Recognition sites for DNA restriction enzymes used for cloning are underlined. A: *c-jun* 5' primer. B: *c-jun* 3' primer. C: *c-fos* 5' primer. D: *c-fos* 3' primer.

Figure 17 shows the respective DNA and amino acid (one letter code) sequences of c-fos and c-jun fragments as fused to TCRs (inserts in pBJ107 and pBJ108). A: c-jun leucine zipper as fused to TCR  $\alpha$  chains. B: c-fos leucine zipper as fused to TCR  $\beta$  chains.

Figure 18 shows the sequences of the synthetic DNA primers used for mutating the unpaired cysteine residue in TCR  $\beta$  chains. The primers were designed for use with the "Quickchange<sup>TM</sup>" method for mutagenesis (Stratagene). A: Mutation of cysteine to serine, forwards (sense) primer, indicating amino acid sequence and the mutation. B: mutation of cysteine to serine, backwards (nonsense) primer. C: mutation of cysteine to alanine, forwards (sense) primer, indicating amino acid sequence and the mutation. D: mutation of cysteine to alanine, backwards (nonsense) primer.

Figure 19 is a schematic representation of a TCR-zipper fusion protein. The four immunoglobulin domains are indicated as domes, with the intrachain disulphide bridges between matching pairs of cysteine residues shown. The numbers indicate amino acid positions in the mature T-cell receptor chains; due to slight variation in chain length after recombination, the lengths of the chains can vary slightly between different TCRs. The residues introduced in the linker sequences are indicated in the one-letter code.

Figure 20 shows the sequences of the synthetic DNA primers used for PCR amplification of TCR  $\alpha$  and  $\beta$  chains. Recognition sites for DNA restriction enzymes are underlined and the amino acid sequences corresponding to the respective TCR chains are indicated over the forward primer sequences. Silent DNA mutations relative to the TCR gene sequences and other DNA

sequences which do not correspond to the TCR genes are shown in lower case letters. A: 5' PCR primer for the human V $\alpha$  10.2 chain of the JM22 Influenza Matrix virus peptide-HLA-A0201 restricted TCR. B: 5' PCR primer for the human V $\beta$ 17 chain of the JM22 Influenza Matrix virus peptide-HLA-5 A0201 restricted TCR. C: 5' PCR primer for the mouse V $\alpha$ 4 chain of the Influenza nucleoprotein peptide-H2-D<sup>b</sup> restricted TCR. D: 5' PCR primer for the mouse V $\beta$ 11 chain of the Influenza nucleoprotein peptide-H2-D<sup>b</sup> restricted TCR. E: 5' PCR primer of the human V $\alpha$ 23 chain of the 003 HIV-1 Gag peptide-HLA-A0201 restricted TCR. F: 5' PCR primer of the human V $\beta$ 5.1 10 chain of the 003 HIV-1 Gag peptide-HLA-A0201 restricted TCR. G: 5' PCR primer of the human V $\alpha$ 2.3 chain of the HTLV-I Tax peptide-HLA-A0201 restricted A6 TCR. H: 5' PCR primer of the human V $\beta$ 12.3 chain of the HTLV-I Tax peptide-HLA-A0201 restricted A6 TCR. I: 5'PCR primer of the human V $\alpha$ 17.2 chain of the HTLV-1 Tax peptide-HLA-A0201 restricted B7 TCR. J: 5' 15 PCR primer of the human V $\beta$ 12.3 chain of the HTLV-I Tax peptide-HLA-A0201 restricted B7 TCR. K: 3' PCR primer for human C $\alpha$  chains, generally applicable. L: 3' PCR primer for human C $\beta$  chains, generally applicable.

Figure 21 shows the predicted protein sequence (one letter code, top) and DNA sequence (bottom) of the soluble HLA-A2/flu matrix restricted TCR  $\alpha$  20 chain from JM22, as fused to the "leucine zipper" domain of c-jun. Mutations introduced into the 5' end of the DNA sequence to enhance expression of the gene in *E.coli* are indicated in small letters, as is the linker sequence between the TCR and c-jun sequences.

Figure 22 shows the predicted protein sequence (one letter code, top) and DNA sequence (bottom) of the soluble HLA-A2/flu matrix restricted TCR  $\beta$  25 chain from JM22, as fused to the "leucine zipper" domain of c-fos. The linker sequence between the TCR and c-fos sequences is indicated in small letters.

Figure 23 shows the predicted protein sequence (one letter code, top) and DNA sequence (bottom) of the soluble H2-D<sup>b</sup>/Influenza virus nucleoprotein

restricted TCR  $\alpha$  chain from murine F5 receptor, as fused to the "leucine zipper" domain of c-jun. Mutations introduced into the 5' end of the DNA sequence to enhance expression of the gene in *E.coli* are indicated in small letters, as is the linker sequence between the TCR and c-jun sequences.

5 Figure 24 shows the predicted protein sequence (one letter code, top) and DNA sequence (bottom) of the soluble H2-D $b$ /Influenza virus nucleoprotein restricted TCR  $\beta$  chain from murine F5 receptor, as fused to the "leucine zipper" domain of c-fos. The linker sequence between the TCR and c-fos sequences is indicated in small letters.

10 Figure 25 shows the predicted protein sequence (one letter code, top) and DNA sequence (bottom) of the soluble HLA-A2/HIV-1 Gag restricted TCR  $\alpha$  chain from patient 003, as fused to the "leucine zipper" domain of c-jun. Mutations introduced into the 5' end of the DNA sequence to enhance expression of the gene in *E.coli* are indicated in small letters, as is the linker sequence between the TCR and c-jun sequences.

15

Figure 26 shows the predicted protein sequence (one letter code, top) and DNA sequence (bottom) of the soluble HLA-A2/HIV-1 Gag restricted TCR  $\beta$  chain from patient 003, as fused to the "leucine zipper" domain of c-fos. The linker sequence between the TCR and c-fos sequences is indicated in small letters.

20 Figure 27 shows the predicted protein sequence (one letter code, top) and DNA sequence (bottom) of the soluble HTLV-1 Tax/HLA-A2 restricted TCR  $\alpha$  chain clone A6 (Garboczi, Utz et al., 1996; Garboczi, Ghosh et al., 1996), as fused to the "leucine zipper" domain of c-jun. Mutations introduced into the 5' end of the DNA sequence to enhance expression of the gene in *E.coli* are indicated in small letters, as is the linker sequence between the TCR and c-jun sequences.

Figure 28 shows the predicted protein sequence (one letter code, top) and DNA sequence (bottom) of the soluble HTLV-1 Tax/HLA-A2 restricted TCR  $\beta$  chain from clone A6 (Garboczi, Utz et al., 1996; Garboczi, Ghosh et al., 1996), as fused to the "leucine zipper" domain of c-fos and the biotinylation tag which acts as a substitute for BirA (Barker and Campbell, 1981; Barker and Campbell, 1981; Howard, Shaw et al., 1985; Schatz, 1993; O'Callaghan, Byford, 1999). The linker sequence between the TCR and c-fos sequences is indicated in small letters. Mutation of the DNA sequence which substitutes a cysteine residue for an alanine residue is indicated in bold and underlined.

Figure 29 shows the predicted protein sequence (one letter code, top) and DNA sequence (bottom) of the soluble HTLV-1 Tax/HLA-A2 restricted TCR  $\alpha$  chain from clone M1OB7/D3 (Ding et al., 1998), as fused to the "leucine zipper" domain of c-jun. The linker sequence between the TCR and c-jun sequences is indicated in small letters.

Figure 30 shows the predicted protein sequence (one letter code, top) and DNA sequence (bottom) of the soluble HTLV-1 Tax/HLA-A2 restricted TCR  $\beta$  chain from clone M10B7/D3 (Ding et al., 1998), as fused to the "leucine zipper" domain of c-fos and the biotinylation tag which acts as a substitute for BirA. The linker sequence between the TCR and c-fos sequences is indicated in small letters. Mutation of the DNA sequence which substitutes an alanine for a cysteine residue is indicated in bold and underlined. Two silent mutations (P-G codons) introduced for cloning purposes and to remove a XmaI restriction site are also indicated in small letters.

Figure 31 shows the predicted protein sequence (one letter code, top) and DNA sequence (bottom) of mutated soluble HTLV-1 Tax/HLA-A2 restricted TCR  $\beta$  chain from clone A6 (Garboczi, Utz et al., 1996; Garboczi, Ghosh et al., 1996), as fused to the "leucine zipper" domain of c-fos and the biotinylation tag which acts as a substitute for BirA (Barker and Campbell, 1981; Barker and Campbell, 1981; Howard, Shaw, 1985; Schatz, 1993;

O'Callaghan, Byford, 1999). The linker sequence between the TCR and c-fos sequences is indicated in small letters. Mutation of the DNA sequence which substitutes a cysteine residue for an alanine residue is indicated in bold and underlined. Also indicated in bold and underlined is a substitution of an 5 asparagine residue for an aspartic acid, a mutation in the constant region which had no detectable functional effect on the soluble TCR.

Figure 32 shows the predicted protein sequence (one letter code, top) and DNA sequence (bottom) of the *c-fos* - biotinylation fusion partner used for TCR  $\beta$  chains. Recognition sites for DNA restriction enzymes are underlined 10 and the borders of the two fusion domains are indicated. Linker sequences are shown in lower case letters.

Figure 33 shows the sequence of a synthetic DNA primer used for PCR amplification of the V $\beta$ -*c-fos* leucine zipper fragment of the human JM22 Influenza Matrix peptide-HLA-A0201.

15 Figure 34 is a set of photographs of gels. a. Preparation of denatured protein for the TCR specific for the 003 HIV gag peptide - HLA-A2 complex analysed by SDS-PAGE. Lane 1: broad-range molecular weight markers (Bio-Rad), lanes 2 & 3: bacteria after induction of protein expression with 0.5 mM IPTG, lanes 4 & 5: purified inclusion bodies solubilised in 6M guanidine buffer. b. 20 Preparation of denatured protein for the biotin-tagged TCR specific for the influenza matrix peptide - HLA-A2 complex analysed by SDS-PAGE. Lane 1: broad-range molecular weight markers (Bio-Rad), lanes 2 & 3:  $\alpha$ - &  $\beta$ -chain purified inclusion bodies solubilised in 6M guanidine buffer. c. Preparation of 25 denatured protein for the biotin-tagged TCR specific for the HTLV tax peptide - HLA-A2 complex analysed by SDS-PAGE. Lanes 1 & 5: broad-range molecular weight markers (Bio-Rad), lanes 2, 3 & 4:  $\alpha$ -,  $\beta$ - & mutant  $\beta$ -chain expression in bacteria after induction of protein expression with 0.5 mM IPTG, lanes 6, 7 & 8:  $\alpha$ -,  $\beta$ - & mutant  $\beta$ -chain purified inclusion bodies solubilised in 6M guanidine buffer.

Figure 35 is a chromatogram showing the elution of the JM22z heterodimer from a POROSPOROS™ 10HQ anion exchange column. Dashed line shows the conductivity which is indicative of a sodium chloride concentration, the solid line shows optical density at 280 nm which is indicative of protein concentration of the eluate. Peak protein containing fractions were pooled for further analysis. Insert shows a chromatogram of elution of purified JM22z from a SuperdexSUPERDEX™ 200 HR column. Arrows indicate the calibration of the column with proteins of known molecular weight. By comparison with these proteins, the refolded JM22z protein has a molecular weight of approximately 74 kDa which is compatible with a heterodimeric protein.

Figure 36 is a photograph showing an SDS-polyacrylamide gel electrophoresis (Coomassie-stained) of the purified JM22z protein. Lanes 1 & 3: standard proteins of known molecular weight (as indicated), lane 2: JM22z protein treated with SDS-sample buffer containing reducing agent (DTT) prior to sample loading, lane 4: JM22z protein treated with SDS-sample buffer in the absence of reducing agents.

Figure 37. a. Purification of the refolded biotin-tagged TCR specific for the influenza matrix peptide - HLA-A2 complex. i. Chromatogram of the elution of the protein from a POROSPOROS™ 10HQ column. Line x indicates absorbance at 280 nm and line y indicates conductivity (a measure of sodium chloride gradient used to elute the protein). Fraction numbers are indicated by the vertical lines. ii. SDS-PAGE of the fractions eluting off the column as in i. Lane 1 contains broad-range molecular weight markers (Bio-Rad) and lanes 2 -13 contain 5  $\mu$ l of fractions 6 - 15 respectively. iii. SDS-PAGE analysis of pooled fractions from i containing biotin-tagged flu-TCR. Lane 1: broad-range molecular weight markers (Bio-Rad), lane 2: biotin-tagged flu-TCR protein. b. Purification of the refolded biotin-tagged TCR specific for the HTLV-tax peptide - HLA-A2 complex. i. Chromatogram of the elution of the protein from a POROSPOROS™ 10HQ column. Line x indicates absorbance

at 280 nm and line y indicates conductivity (a measure of sodium chloride gradient used to elute the protein). Fraction numbers are indicated in by the vertical lines. ii. SDS-PAGE of the fractions eluting off the column as in i.

Lane 1 contains broad-range molecular weight markers (Bio-Rad) and lanes 2

5 - 10 contain 5µl of fractions 3 - 11 respectively. iii. SDS-PAGE analysis of pooled fractions from i. of biotin-tagged tax-TCR. Lane 1: broad-range molecular weight markers (Bio-Rad), lane 2: biotin-tagged tax-TCR protein, lane 3: mutant biotin-tagged tax-TCR protein.

Figure 38 is a chromatogram showing elution of biotin-tagged soluble TCR

10 after biotinylation with BirA enzyme from a SuperdexSUPERDEX™ 200 HR column equilibrated in PBS. The biotinylated TCR elutes at around 15-16 minutes and the free biotin elutes at around 21 minutes. Fractions containing biotinylated soluble TCR are pooled for future use.

Figure 39 is a set of photographs of gels. Assessment of biotinylation of the

15 biotinylated TCRs. a. SDS-PAGE of refolded TCRs and inclusion body preparations. Lane 1: broad-range molecular weight markers (Bio-Rad), lane 2: Biotinylated flu-TCR, lane 3: Biotinylated tax-TCR, lane 4: Biotinylated mutant tax-TCR, lane 5: HIV gag-TCR, (not biotin-tagged); b. Western blot of a gel identical to a. except that the broad-range markers were biotin labelled 20 (Bio-Rad). Staining was with avidin-HRP conjugate to show biotinylated proteins and visualisation was with Opti-4CN (Bio-Rad).

Figure 40 illustrates JM22z binding to different HLA-A2-peptide complexes.

(a inset) The specificity of the interaction between JM22z and HLA-A2-flu is demonstrated by comparing the SPR response from passing the TCR over a

25 flow cell coated with 1900 RU of HLA-A2-flu to the responses from passing the TCR over two other flow cells one coated with 4200 RU of HLA-A2-pol, the other coated with 4300 RU of CD5. Background responses at different JM22z concentrations were measured on 1700 RU of HLA-A2-pol (a). The background value was subtracted from the specific response measured on

1900 RU of HLA-A2-flu (b) and plotted against concentration (c). The  $K_d$  of 13  $\mu\text{M}$ , estimated by non-linear curve fitting was in accordance with the  $K_d$  of 12  $\mu\text{M}$  calculated on basis of a Scatchard plot of the same data.

Figure 41 is a graph showing the result of ~~Biacore 2000™~~BIACORE 2000™ analysis of wild-type and mutant soluble biotinylated tax TCR. 5  $\mu\text{l}$  of wild-type tax TCR at a concentration of 2.2 mg/ml and then mutant tax TCR at a concentration of 2.4 mg/ml was flowed over four flow cells with the following proteins attached to the surface: A: tax-pMHC complex, B/C: flu-pMHC complex, D: OX68 control protein. Both wild-type and mutant proteins bind similarly to the specific pMHC complex.

Figure 42 shows the effect of soluble CD8aa binding on soluble TCR binding to the same HLA-A2-flu complex. (A) TCR or TCR plus 120  $\mu\text{M}$  soluble CD8 were injected into a control flow cell coated with 4100 RU of an irrelevant protein (CD5) and a probe flow cell coated with 4700 RU of HLA-A2-flu. After subtraction of the background, the calculated equilibrium response values at different concentrations of TCR alone (open circles) or in combination with 120  $\mu\text{M}$  soluble CD8 (closed circles) is shown. Also shown is the value of CD8 alone (open triangles) and the calculated difference between TCR + CD8 and TCR alone (open squares). (B) The time-dependence of the responses on 4700 RU of immobilised HLA-A2-flu of 49  $\mu\text{M}$  TCR alone (open circles) or in combination with 120  $\mu\text{M}$  CD8 (closed circles) at 25° C and a flow rate of 5  $\mu\text{l}/\text{min}$  is shown (The values are corrected for background contributions measured on 4100 RU of immobilised CD5); the off-rate of TCR is not affected by the simultaneous CD8 binding.

Figure 43. Tetramerisation of biotinylated TCR using extravidin. Gel filtration using a ~~Superdex~~SUPERDEX™ 200 HR column shows that biotinylated TCR and extravidin combine to form an oligomer of higher molecular weight than either protein. Gel filtration chromatograms: A. Extravidin B. Biotinylated TCR C. TCR tetramers.

Figure 44. Tetramerisation of biotinylated TCR using RPE-modified streptavidin. Gel filtration using a Superdex**SUPERDEX™** 200 HR column shows that biotinylated TCR and streptavidin-RPE combine to form an oligomer of higher molecular weight than either protein. Gel filtration chromatograms: A. Streptavidin-RPE B. Biotinylated TCR C. TCR-RPE tetramers.

Figure 45A is a graph showing the results of BIAcore**BIACORE™** analysis of biotinylated soluble flu-TCR. 5  $\mu$ l of flu-TCR at a concentration of 1 mg/ml was flowed over three flow-cells with the following attached via streptavidin - i: non-specific control protein, ii: flu matrix pMHC, iii: tax pMHC. Figure 45B. Figure 45B is a graph showing the results of BIAcore**BIACORE™** analysis of flu-TCR tetramers. 5  $\mu$ l of flu-TCR tetramer solution at a concentration of 0.05 mg/ml was flowed over three flow-cells with the following attached via streptavidin - i: non-specific control protein, ii: flu matrix pMHC, iii: tax pMHC.

Figure 46A is a graph showing the results of BIAcore**BIACORE™** analysis of biotinylated soluble tax-TCR. 5  $\mu$ l of flu-TCR at a concentration of 1 mg/ml was flowed over three flow-cells with the following attached via streptavidin - i: non-specific control protein, ii: flu matrix pMHC, iii: tax pMHC. Figure 46B is a graph showing the results of BIAcore**BIACORE™** analysis of tax-TCR tetramers. 5  $\mu$ l of flu-TCR tetramer solution at a concentration of 0.05 mg/ml was flowed over three flow-cells with the following attached via streptavidin - i: non-specific control protein, ii: flu matrix pMHC, iii: tax pMHC.

Figure 47. FACS analysis of T2 cells pulsed with varying levels of peptide and stained with TCR tetramers specific for either influenza matrix peptide or HTLV tax peptide. A. Gating of cells for analysis. B. Staining of T2 cells pulsed with: "Data.001"= 0 peptide; "Data.007"=  $10^{-4}$  M flu peptide; "Data.009"=  $10^{-5}$  M flu peptide; "Data.010"=  $10^{-6}$  M flu peptide; "Data.003"=  $10^{-4}$  tax peptide, all stained with 5  $\mu$ g flu-TCR tetramers labelled with RPE. C. Staining of T2 cells pulsed with: "Data.002"= 0 peptide; "Data.004"=  $10^{-4}$  M tax

peptide; "Data.005"=  $10^{-5}$  M tax peptide; "Data.006"=  $10^{-6}$  M tax peptide; "Data.008"=  $10^{-4}$  flu peptide, all stained with 5  $\mu$ g tax-TCR tetramers, labelled with RPE.

Figure 48. FACS analysis of .45 cells pulsed with varying levels of peptide  
5 and stained with TCR tetramers specific for either influenza matrix peptide or  
HTLV tax peptide. A. Gating of cells for analysis. B. Staining of .45 cells  
pulsed with: "Data.002"= 0 peptide; "Data.004"=  $10^{-4}$  M flu peptide;  
"Data.006"=  $10^{-5}$  M flu peptide; "Data.010"=  $10^{-4}$  tax peptide, all stained with 5  
 $\mu$ g flu-TCR tetramers labelled with RPE. C. Staining of .45 cells pulsed with:  
10 "Data.003"= 0 peptide; "Data.011"=  $10^{-4}$  M tax peptide; "Data.013"=  $10^{-5}$  M tax  
peptide; "Data.015"=  $10^{-6}$  M tax peptide; "Data.005"=  $10^{-4}$  flu peptide, all  
stained with 5  $\mu$ g tax-TCR tetramers labelled with RPE.

Figure 49. FACS analysis of T2 cells pulsed with varying levels of peptide  
and stained with TCR-coated latex beads ('Fluospheres' – Molecular Probes)  
15 with red fluorescent label. A. Gating of unstained cells for analysis. B. Gating  
of stained cells for analysis. Note shift is side-scatter caused by the mass of  
bead binding to the cells. C. Staining of T2 cells pulsed with: "Data.002"= 0  
peptide-, "Data.004"=  $10^{-4}$  M flu peptide; "Data.006"=  $10^{-5}$  M flu peptide;  
"Data.007"=  $10^{-6}$  M flu peptide, all stained with 10  $\mu$ l flu-TCR-coated beads.  
20 D. Staining of T2 cells pulsed with: "Data.003"= 0 peptide; "Data.009"=  $10^{-4}$   
M tax peptide; "Data.010"=  $10^{-5}$  M tax peptide; "Data.011"=  $10^{-6}$  M tax  
peptide, all stained with 10  $\mu$ l tax-TCR-coated beads.

## EXAMPLES

In the following examples, the general methods and materials set out below  
25 were used.

### Materials

Restriction enzymes (NdeI, BamHI, HindIII, Bsu36I, XmaI) were from New  
England Biolabs.

Tris pH 8.1 was made up as a 2M stock solution from equal parts of Tris base and Tris-HCl both from USB.

EDTA (Sigma) was made up as a 0.5M stock solution and the pH was adjusted to 8.0 using 5M NaOH (Sigma).

5 Glutathione in oxidised and reduced forms was from Sigma.

Cystamine and cysteamine were from Sigma.

Sodium Chloride was from USB and was made up to a 4M stock solution.

Miniprep kits for plasmid purification were from Qiagen.

PCR purification kits were from Qiagen.

10 DTT was from Sigma.

Guanidine was from Fluka.

Urea was from Sigma.

RPMI medium was from Sigma.

PBS was made up from tablets from Oxoid.

15 Glycerol was from BDH.

### General Methods

Bacterial media (TYP media) were prepared as follows:

160 g Yeast Extract (Difco), 160 g Tryptone (Difco), 50 g NaCl (USB) and 25

g K<sub>2</sub>HP0<sub>4</sub> (BDH) were dissolved in 2 L demineralised water. 200 ml aliquots

20 of this solution were measured into 10 x 2 L conical flasks and made up to 1 L by adding 800 ml demineralised water. Flasks were covered with four layers of aluminum foil, labelled and autoclaved. After cooling, the flasks were stored at room temperature out of direct sunlight prior to use.

Protein concentrations were measured using a Pierce Coomassie-binding

25 assay and BSA as a standard protein. Briefly, 0-25 µg BSA standards in a

volume of 1 ml water were prepared from a stock 2 mg/ml BSA (Pierce) in 4 ml plastic cuvettes. Approximately 10 µg of unknown protein was made up to 1 ml with water in the same way. 1 ml Pierce Coomassie reagent was added to each cuvette and the contents were thoroughly mixed. The optical density 5 was measured within 15 minutes at 595 nm using a Beckman DU-530 UV spectrophotometer. A linear regression was performed on the results from the BSA standards (linearity was good up to 25 µg BSA) and the unknown protein concentration was estimated by interpolation with these results.

Gel filtration chromatography was performed on a Pharmacia  
10 FPLCPHARMACIA FPLC™ system equipped with a computer controller. Protein elution was monitored using a UV-M 11 system measuring absorbance at 280 nm wavelength. For small-scale separations, a SuperdexSUPERDEX™ 200 HR 10/30 column was employed and sample was loaded using a 1 ml loop. Prior to running the column was equilibrated 15 with 30 ml of PBS and the sample was run at 0.5 ml/min with 1 ml fractions being collected. For large-scale separations, a SuperdexSUPERDEX™ 75 or 200 PG 26/60 column was used with a 10 ml superloop. In this case 5 or 10 ml samples were collected and the column was run at 4 ml/min. All separations were performed at room temperature.

20 Ion exchange chromatography was performed on a BiocadBIOCAD™ Sprint system (Perkin-Elmer). For cation exchange, a 20 HS or a 50 HS column was employed. For anion exchange, a 10 HQ, 20 HQ or a 50 HQ column was employed. Columns were run using the recommended buffers attached to a 6-way mixer. Small samples ( 5 - 25 ml ) were injected using a 5 ml 25 injection loop. Larger samples ( > 100 ml ) were injected using one of the buffer lines. 1 ml fractions were collected during the elution phase of the column run. Protein elution was measured by in-line absorbance at 280 nm.

SDS polyacrylamide gel electrophoresis (SDS-PAGE) was performed using a Bio-Rad Mini-Protean II gel set. Gels were poured prior to use using the

following procedure. The gel plate assembly was prepared and checked to ensure against leakage. Then the following mixture was prepared: 12 % acrylamide / bisacrylamide (from a 30 % acrylamide / 0.8 % bisacrylamide stock solution (National Diagnostics)), 0.375 M Tris pH 8.8 (from a 1.5 M stock of the same pH), 0.1 % SDS (from a 10 % SDS stock solution), 0.05 % Ammonium persulphate (from a 10% stock of the same, stored at 4 C) and 0.1 % TEMED (Sigma). The mixture was immediately poured into the gel plate assembly and water-saturated butanol was layered on top to ensure a flat upper surface. After the gel had set (10 - 15 minutes minimum), the 5 stacking gel was mixed as follows. 4 % acrylamide (from stock as before), 0.125 M Tris pH 6.8 (from 0.5 M stock of the same pH), 0.1 % SDS, 0.05 % Ammonium persulphate, and 0.2 % TEMED. The butanol was removed from the surface of the resolving gel by absorption onto a tissue and the stacking 10 gel mixture was poured on top of the resolving gel. A gel comb was inserted taking care to avoid introducing air bubbles into the gel and the stacking gel was allowed to set for a minimum of 5 minutes.

15

The gel was then assembled into the gel apparatus and running buffer (3 g/L Tris-base, 14.4 g/L glycine, 1 g/L SDS (diluted from a 10x concentrated stock solution) was poured into the apparatus at the anode and the cathode. After 20 removing the gel comb, the wells were washed out with running buffer to prevent residual acrylamide mixture from setting in the bottom of the wells. Samples were prepared by mixing protein 1:1 with the following mixture: 4 % SDS, 0.125 M Tris pH 6.8, 20 % glycerol, 10 %  $\beta$ -mercaptoethanol, 1 % bromophenol blue (Sigma). Samples were then heated to 95°C for 2 minutes 25 and cooled prior to loading up to 25  $\mu$ l into the wells in the stacking gel. Approximately 1 - 10  $\mu$ g of protein was usually loaded to ensure good staining and running of the gel. After loading, the gels were run at a constant voltage of 200 V for approximately 40 minutes or until the bromophenol blue dye was approximately 5 mm from the end of the gel.

After completing of the electrophoresis, the gels were removed from the apparatus and carefully dropped into a 0.1 % solution of Coomassie R-250 (Sigma) in 10 % acetic acid, 40 % methanol, 50 % water. Gels were then gently agitated for at least 30 minutes prior to destaining in several changes 5 of 10 % acetic acid, 40 % methanol, 50 % water until the gel background was clear. Gels were then stored in water and recorded using a UVP gel documentation system consisting of a light box, a digital camera and a thermal printer.

### **Example 1 - Recombinant Soluble TCR**

10 A recombinant soluble form of the heterodimeric TCR molecule was engineered as outlined in Figure 1. Each chain consists of membrane-distal and -proximal immunoglobulin domains which are fused via a short flexible linker to a coiled coil motif which helps stabilise the heterodimer.

15 The TCR constant domains have been truncated immediately before cysteine residues which *in vivo* form an interchain disulphide bond. Consequently, the two chains pair by non-covalent quaternary contacts, and this is confirmed in Figure 2b. As the Fos-Jun zipper peptide heterodimers are also capable of forming an interchain disulphide immediately N-terminal to the linker used (O'Shea *et al.* 1989), the alignment of the two chains relative to each other 20 was predicted to be optimal. Fusion proteins need to be joined in a manner which is compatible with each of the separate components, in order to avoid disturbing either structure.

cDNA encoding alpha and beta chains of a TCR specific for the influenza-  
matrix protein 58-66 epitope in HLA-A2 was obtained from a V $\beta$ 17+ human  
25 CTL clone (JM22) by anchored PCR as described previously (Moss *et al.* 1991).

Alpha and beta TCR-zipper constructs pJM22 $\alpha$ -Jun and pJM22 $\beta$ -Fos were separately constructed by amplifying the variable and constant domain of

each chain using standard PCR technology and splicing products onto leucine zipper domains from the eukaryotic transcription factors Jun and Fos respectively (See Figure 1). These 40 amino acid long sequences have been shown to specifically heterodimerise when refolded from synthetic peptides, 5 without the need for a covalent interchain linkage (O'Shea *et al.* 1989).

Primers were designed to incorporate a high AT content immediately 3' to the initiation codon (to destabilise mRNA secondary structure) and using *E.coli* codon preferences, in order to maximise expression (Gao *et al.*.. The spare 10 cysteine in the TCR beta constant domain was mutated to serine to ensure prevention of incorrect disulphide bonding during refolding.

DNA constructs were ligated separately into the *E.coli* expression vector pGMT7. Plasmid digests and DNA sequencing confirmed that the constructs 10 were correct.

In detail the procedures used were as follows.

15 Expression of TCR zipper chains and purification of denatured inclusion bodies: GFG020 and GFG021, the pGMT7 expression plasmids containing JM22 $\alpha$ -Jun and JM22 $\beta$ -Fos respectively were transformed separately into *E.coli* strain BL21pLysS, and single ampicillin-resistant colonies were grown at 37°C in TYP (ampicillin 100 $\mu$ g/ml) medium to OD<sup>600</sup> of 0.4 before inducing 20 protein expression with 0.5mM IPTG. Cells were harvested three hours post-induction by centrifugation for 30 minutes at 4000rpm in a Beckman J-6 $\beta$ . Cell pellets were resuspended in a buffer containing 50mM Tris-HCl, 25% (w/v) sucrose, 1mM NaEDTA, 0.1% (w/v) NaAzide, 10mM DTT, pH 8.0. After an overnight freeze-thaw step, resuspended cells were sonicated in 1 minute 25 bursts for a total of around 10 minutes in a Milsonix XL2020 sonicator using a standard 12mm diameter probe. Inclusion body pellets were recovered by centrifugation for 30 minutes at 13000rpm in a Beckman J2-21 centrifuge. Three detergent washes were then carried out to remove cell debris and membrane components. Each time the inclusion body pellet was

homogenised in a Triton buffer (50mM Tris-HCl, 0.5% Triton-XTRITON-X™100, 200mM NaCl, 10mM NaEDTA, 0.1% (w/v) NaAzide, 2mM DTT, pH 8.0) before being pelleted by centrifugation for 15 minutes at 13000rpm in a Beckman J2-21. Detergent and salt was then removed by a similar wash in

5 the following buffer: 50mM Tris-HCl, 1 mM NaEDTA, 0.1 % (w/v) NaAzide, 2mM DTT, pH 8.0. Finally, the JM22α-Jun and JM22β-Fos inclusion body pellets were dissolved separately in a urea solution (50mM MES, 8M urea, 10mM NaEDTA, 2mM DTT, pH 6.5) for 3 to 4 hours at 40°C. Insoluble material was pelleted by centrifugation for 30 minutes at 1 3000rpm in a

10 Beckman J2-21, and the supernatant was divided into 1ml aliquots and frozen at -70°C. Inclusion bodies solubilised in urea were quantitated with a Bradford dye-binding assay (Biorad). For each chain a yield of around 100mg of purified inclusion body was obtained from one litre of culture. Each inclusion body (JM22α-Jun, JM22β-Fos) was solubilised in urea solution at a

15 concentration of around 20mg/ml, and was estimated from gel analysis to be around 90% pure in this form (data not shown).

*Co-refolding of TCR-zipper fusion proteins:*

Initial refolding experiments using a standard refolding buffer (100mM Tris pH 8.5, 1M L-Arginine, 2mM EDTA, 5mM reduced Glutathione, 0.5mM oxidised

20 Glutathione, 0.2mM PMSF) resulted in severe protein precipitation which was dependent upon the presence of the zipper domains. The fact that this phenomenon occurred at concentrations below the dissociation constant of zipper dimerisation (i.e. when most zipper helices are expected to be monomeric) suggested additional forces were stabilising misfolded species.

25 The most likely explanation is that the entirely alpha-helical zipper domains fold first and that their transient heterodimerisation induces inter-chain aggregation of partially folded intermediates of the more complex immunoglobulin domains. The refolding buffer was therefore altered to include 5M urea in order to prevent hydrophobic interactions between partially

30 folded immunoglobulin domains and allow individual chains to fold completely

before heterodimerisation. This step is sufficient to prevent precipitation occurring, and allows correctly folded TCR-zipper heterodimers to assemble with acceptable yields using the following protocol.

Urea-solubilised stocks of TCR-zipper chains JM22 $\alpha$ -Jun and JM22 $\beta$ -Fos  
5 were renatured by dilution co-refolding. Approximately 30mg (i.e. 1~Mole) of each solubilised inclusion body chain was thawed from frozen stocks and a further pulse of DTT (4 $\mu$ moles/ml) was added to ensure complete reduction of cysteine residues. Samples were then mixed and the mixture diluted into 15ml of a guanidine solution (6 M Guanidine-hydrochloride, 10mM Sodium  
10 Acetate, 10mM EDTA), to ensure complete chain denaturation. The guanidine solution containing fully reduced and denatured TCR-zipper chains was then injected into 1 litre of the following refolding buffer: 100mM Tris pH 8.5, 400mM L-Arginine, 2mM EDTA, 5mM reduced Glutathione, 0.5mM oxidised Glutathione, 5M urea, 0.2mM PMSF. The solution was left for 24  
15 hrs. The refold was then dialysed twice, firstly against 10 litres of 100mM urea, secondly against 10 litres of 100mM urea, 10mM Tris pH 8.0. Both refolding and dialysis steps were carried out at 6-8°C.

*Purification of refolded TCR-zipper:*

TCR-zipper JM22zip was separated from degradation products and impurities  
20 by loading the dialysed refold onto a POROSPOROS™ 10HQ analytical anion exchange column in seven 200ml aliquots and eluting bound protein with a gradient of 0-400mM NaCl over 50 column volumes using a BioGadBIOCAD™ workstation (Perseptive Biosystems). Non-covalently associated heterodimer eluted in a single peak at approximately 100mM  
25 NaCl. Peak fractions (typically containing heterodimer at a concentration of 100-300 $\mu$ g/ml) were stored at 4°C before being pooled and concentrated. The yield of heterodimer is approximately 15%.

*Characterisation of the refolded TCR-zipper JM22zip:*

The JM22zip heterodimer purified by anion exchange elutes as an approximately 70kDa protein from a SuperdexSUPERDEX™ 200 gel filtration sizing column (Pharmacia). It is especially important to include gel filtration steps prior to surface plasmon resonance binding analysis since accurate

5 affinity and kinetic measurements rely on monomeric interactions taking place. In this way, higher order aggregates can be excluded from the soluble protein fraction used for analysis. In particular, aggregates cause artificially slow association and dissociation rate constants to be detected.

The oxidation state of each chain has been examined by a reducing/non-

10 reducing gel analysis in Fig 2. In the presence of SDS, the non-covalently associated heterodimer is dissociated into alpha and beta chains. If DTT is used in loading buffer, the two chains run either side of the 31 kDa marker. In the absence of such denaturants both chains still behave as a single species, but the mobility of each increases, which suggests each chain has formed a  
15 single, disulphide-bonded species (Garboczi *et al.* 1996).

The antibody reactivity of refolded receptor has been tested using surface plasmon resonance on a BiacoreBIACORE 2000™ machine (Biacore). The TCR-zipper JM22z was immobilised to a dextran matrix (CM chip) binding surface at pH 5.5 using standard amine coupling methods. A variable region  
20 antibody specific for the beta chain (V $\beta$  17) specifically binds to the immobilised receptor, implying correct conformation.

#### *Stability:*

The soluble TCRs expressed as alpha-jun and beta-fos leucine zipper fusions are stable over periods of months and are therefore suitable for the detection  
25 of specific antigens presented by class I MHC.

#### **Example 2 - Kinetics and Affinity Study of human TCR-viral peptide-MHC**

*Specific binding of refolded TCR-zipper to peptide-MHC complexes:*

A surface plasmon resonance biosensor (Biacore BIACORE™) was used to analyse the binding of a TCR-zipper (JM22zip, specific for HLA-A2 influenza matrix protein M58-66 complex) to its peptide-MHC ligand (see Fig. 3). We facilitated this by producing single pMHC complexes (described below) which

5 can be immobilised to a streptavidin-coated binding surface in a semi-oriented fashion, allowing efficient testing of the binding of a soluble T-cell receptor to up to four different pMHC (immobilised on separate flow cells) simultaneously. Manual injection of HLA complex allows the precise level of immobilised class I molecules to be manipulated easily.

10 Such immobilised complexes are capable of binding both T-cell receptors (see Fig. 3) and the coreceptor CD8 $\alpha\alpha$ , both of which may be injected in the soluble phase. Specific binding of TCR-zipper is obtained even at low concentrations (at least 40 $\mu$ g/ml), implying the TCR zipper is relatively stable. The pMHC binding properties of JM22z are observed to be qualitatively and

15 quantitatively similar if TCR is used either in the soluble or immobilised phase. This is an important control for partial activity of soluble species and also suggests that biotinylated pMHC complexes are biologically as active as non-biotinylated complexes.

*Preparation of chemically biotinylated HLA complexes:*

20 Methods for the production of soluble, recombinant single peptide class I HLA complexes have already been described (Garboczi *et al.*, 1992). These have been modified in order to produce HLA complexes which have  $\beta$ -2-microglobulin domains chemically biotinylated and may therefore be immobilised to a streptavidin coated binding chip and used for surface

25 plasmon binding studies.

$\beta$ -2-microglobulin was expressed and 40mg refolded in a standard refolding buffer (100mM Tris pH 8.0, 400mM L-Arginine, 2mM EDTA, 5mM reduced Glutathione, 0.5mM oxidised Glutathione, 0.1mM PMSF) essentially as described (Garboczi *et al.* 1992). After an optional gel filtration step, protein

was exchanged to 0.1M Sodium Borate pH 8.8, and finally concentrated to 5-10mg/ml.  $\beta$ -2-microglobulin was also quantitated using the Bradford assay (Biorad). A 5 molar excess of biotin hydroxysuccinimide (Sigma) was added from a stock made up at 10mg/ml in DMSO. The reaction was left for 1 hour 5 at room temperature, and stopped with 20  $\mu$ l of 1M

Ammonium Chloride/250 $\mu$ g of biotin ester used. Refolded HLA complex was separated from free biotin and free biotinylated beta-2-microglobulin using a SuperdexSUPERDEX™ 200 gel filtration sizing column (Pharmacia). Streptavidin was immobilised by standard amine coupling methods.

10 *Conclusions:*

Thus, the protein refolding methods described in Example 1 produce a stable, correctly folded, functional recombinant receptor fusion protein which is suitable for biophysical analysis using an optical biosensor. This has provided a reagent used to carry out a detailed affinity and kinetic analysis of 15 a human TCR-pMHC interaction. The effects of T-cell co-receptor-MHC and TCR-pMHC interactions on each other have also been studied. The recombinant techniques used are applicable in principle to both murine and human TCRs, both class I and class II - restricted, and will enable similar analyses of a range of TCRs. This would allow various questions to be 20 addressed, such as the span of TCR affinities within an antiviral response, the properties of dominantly selected receptors and the kinetic requirements for receptor triggering. The methods also provide a way of verifying the ligand specificity of a TCR prior to crystallization trials, and may also have implications for the recombinant production of other cell surface receptors.

25 **Example 3 - Biotinylation and tetramerisation of soluble T-cell receptors**

2.5 ml purified soluble TCR prepared as described in Example 1 (~0.2 mg/ml) was buffer exchanged into biotinylation reaction buffer (10 mM Tris pH 8.0, 5 mM NaCl, 7.5 mM MgCl<sub>2</sub>) using a PD-10 column (Pharmacia). The eluate

(3.5 ml) was concentrated to 1 ml using a centricon concentrator (Amicon) with a 10 kDa molecular weight cut-off. This was made up to 5mM with ATP added from stock (0.1 g/ml adjusted to pH 7.0).

A cocktail of protease inhibitors was added: leupeptin, pepstatin and PMSF (0.1 mM), followed by 1 mM biotin (added from 0.2M stock) and 5 µg/ml enzyme (from 0.5 mg/ml stock). The mixture was then incubated overnight at room temperature. Excess biotin was removed from the solution by dialysis against 10 mM Tris pH 8.0, 5mM NaCl (200 volumes, with 2 changes at 4°C). The protein was then tested for the presence of bound biotin by blotting onto nitrocellulose followed by blocking with 5% skimmed milk powder, and detection using streptavidin-HRP conjugate (Biorad). Tetramerisation of the biotinylated soluble TCR was with either extravidin-RPE or extravidin-FITC conjugate (Sigma). The concentration of biotin-soluble TCR was measured using a Coomassie binding protein assay (Pierce), and a ratio of extravidin conjugate to soluble TCR of 0.224 mg / mg TCR was calculated to achieve saturation of the extravidin by biotinylated TCR at a ratio of 1:4. The extravidin conjugate was added in aliquots of 1/10th of the total added, on ice, for at least 15 minutes per aliquot (to ensure saturation of the extravidin). Soluble TCR tetramers were stored at 4C in the dark. The tetramers are extremely stable over a period of months.

**Example 4 - Expression, refolding and site-specific biotinylation of soluble α/β TCR**

a) Engineering of TCR α and β chains.

A recombinant soluble form of the heterodimeric TCR molecule was engineered as outlined in Figure 7. Each chain consists of membrane-distal and -proximal immunoglobulin domains which are fused via a short flexible linker to a coiled coil motif which helps stabilise the heterodimer.

Figures 4 to 6 and 11 to 14 show the DNA coding sequences and corresponding amino acid sequences for various TCR alpha and beta chains

from TCR having different specificities. This example concentrates on the TCR represented by the sequences of figures 4 to 6 but the methods disclosed can be similarly performed using the TCRs given in figures 11 to 14.

5 The TCR constant domains have been truncated immediately before cysteine residues which *in vivo* form an interchain disulphide bond. Consequently the two chains pair by non-covalent quaternary contacts. As the Fos-Jun zipper peptide heterodimers are also capable of forming an interchain disulphide immediately N-terminal to the linker used (O'Shea *et al.* 1989), the alignment  
10 of the two chains relative to each other was predicted to be optimal. Fusion proteins need to be joined in a manner which is compatible with each of the separate components, in order to avoid disturbing either structure.

cDNA encoding alpha and beta chains of a TCR specific for the influenza-matrix protein 58-66 epitope in HLA-A2 was obtained from a V $\beta$ 17+ human  
15 CTL clone (JM22) by anchored PCR as described previously (Moss *et al.* 1991).

Alpha and beta TCR-zipper constructs pJM22( $\alpha$ -Jun and pJM22 $\beta$ -Fos were separately constructed by amplifying the variable and constant domain of each chain using standard PCR technology and splicing products onto  
20 leucine zipper domains from the eukaryotic transcription factors Jun and Fos respectively. These 40 amino acid long sequences have been shown to specifically heterodimerise when refolded from synthetic peptides, without the need for a covalent interchain linkage (O'Shea *et al.* 1989).

25 Primers were designed to incorporate a high AT content immediately 3' to the initiation codon (to destabilise mRNA secondary structure) and using *E.coli* codon preferences, in order to maximise expression (Gao *et al.* 1998). The spare cysteine in the TCR beta constant domain was mutated to serine to ensure prevention of incorrect disulphide bonding during refolding.

The fused DNA and protein sequences are indicated in Figures 4 and 5. In order to enable the site-specific biotinylation of the  $\beta$  chain of this TCR a DNA sequence encoding a so-called "biotin-tag" was engineered into the 3' end of the gene expressing soluble V $\beta$ 17. The following PCR primers were

5 employed for the engineering of this DNA construct:

5'-GCTCTAGACATATGGGCCAGTGGATTCTGGAGTCAC-3'

and

5'-

GGGGGAAGCTTAATGCCATTCGATTTCTGAGCTTCAAAAATATCGTT

10 CAGACCACCACCGGATCCGTAAGCTGCCAGGATGAACCTCTAG-3'.

The resulting PCR product was digested with restriction enzymes NdeI and HindIII (New England Biolabs) and ligated with T4 DNA ligase (New England Biolabs) into the vector pGMT7 (Studier *et al.* 1990). Figure 6 shows the DNA sequence of the insert in this construct and the deduced protein

15 sequence.

b) Expression of TCR chains.

Expression and refolding of a TCR with specificity for the Influenza virus Matrix peptide presented by HLA-A\*0201 was carried out as follows:

TCR  $\alpha$  and  $\beta$  chains were expressed separately in the *E.coli* strain

20 BL21DE3pLysS under the control of the vector pGMT7 in TYP media (1.6% bacto-tryptone, 1.6% yeast extract, 0.5% NaCl, 0.25% K2HP04).

Expression was induced in mid-log phase with 0.5 mM IPTG and, after 3-5 hours, bacteria were harvested by centrifugation. The bacterial cells were lysed by resuspension in 'lysis buffer' (10 mM EDTA, 2 mM DTT, 10 mM Tris

25 pH 8, 150 mM NaCl, 0.5 mM PMSF, 0.1 mg/ml lysozyme, 10% glycerol)

followed by addition of 10 mM MgCl<sub>2</sub> and 20 ug/ml DNaseI, incubation for 20 minutes on ice, and sonication using a probe sonicator in 10x bursts of 30 seconds. The protein, in inclusion bodies, was then purified by several washes (usually 3) of 'Triton buffer' (0.5% Triton TRITON-X™-100, 50 mM

5 Tris pH8, 100 mM NaCl, 0.1 % sodium azide, 10 mM EDTA, 2 mM DTT) using centrifugation at 15,000 rpm for 20 minutes to pellet the inclusion bodies and a 'dounce' homogeniser to resuspend them. Detergent was removed from the preparation with a single wash of 50 mM Tris pH 8, 100 mM NaCl, 10 mM EDTA, 2 mM DTT and the protein was solubilised with 'urea 10 buffer' (20 mM Tris pH 8, 8 M urea, 10% glycerol, 500 mM NaCl, 10 mM EDTA, 2 mM DTT). After end-over-end mixing overnight at 4°C, the solution was clarified by centrifugation, and the solubilised protein was stored at -70°C. The protein concentration was measured by a Coomassie-binding assay (Pierce).

15 c) Refolding of the TCR.

Urea-solubilised protein in equal proportions was further denatured in 'guanidine buffer' (6 M guanidine-HCl, 10 mM sodium acetate pH 5.5, 10 mM EDTA, 2 mM DTT) at 37°C. This solution was added to refolding buffer (5 M urea, 100 mM Tris pH 8, 400 mM L-arginine, 5 mM reduced glutathione, 0.5 20 mM oxidised glutathione, 0.1 mM PMSF) on ice ensuring rapid mixing. After >12 hours at 40°C, the solution was dialysed against 10 volumes of water, then 10 volumes of 10 mM Tris pH 8, 100 mM urea. The protease inhibitor PMSF was added at all stages to minimise proteolytic loss of the biotinylation tag on the TCR.

25 d) Purification of the TCR.

The dilute solution of the TCR was filtered through a 0.45 micron filter to remove aggregated protein and was then loaded onto a P<sub>OROSPOROS</sub>™ 10HQ column. The refolded TCR was eluted with a gradient of sodium

chloride in 10 mM Tris pH 8 and 1 ml fractions were collected and analysed by SIDS-PAGE. Fractions containing TCR were pooled and concentrated to 1 ml using a 30 kDa cut-off centrifugal concentrator.

e) Biotinylation of the TCR.

5 The 1 ml of TCR solution was made up to 7.5 mM ATP using buffered ATP, 5 mM MgC12, 1 mM biotin, and a cocktail of protease inhibitors was added which included PMSF, leupeptin, and pepstatin. Finally, the enzyme BirA was added to a final concentration of 5 µg/ml and the reaction was allowed to proceed overnight at room temperature. The TCR was then separated from  
10 free biotin by gel filtration. Fractions containing biotinylated TCR were pooled and protease inhibitor cocktail was added. Protein concentration was also determined. Figure 7 shows a schematic diagram of the soluble, biotinylated TCR.

**Example 5 - Production of TCR tetramers and TCR-coated beads**

15 In order to tetramerise the biotinylated TCR, extravidin (Sigma) was added at a 1:4 molar ratio. Fluorescently labelled extravidin was used for cell-labelling experiments. A step-wise addition was employed to achieve saturation of the extravidin, allowing for some incompleteness in the biotinylation reaction and some inaccuracy in the protein determinations. 15 minutes on ice was  
20 allowed between each addition of extravidin for binding, followed by at least overnight at 4°C after the final addition. Tetramerisation was confirmed by gel filtration of a small sample of the solution on a calibrated  
SuperdexSUPERDEX™ 200 column (Pharmacia). TCR tetramer solution was then stored at 4°C in the presence of protease inhibitor cocktail and  
25 0.05% sodium azide. For TCR tetramer production, see Figures 4-7.

A similar approach can be used to coat various types of beads or other solid supports with soluble TCR. Avidin/streptavidin-coated beads can be obtained from commercial sources (for instance, DynabeadsDYNABEADS™ from

DYNAL, Oslo, Norway, or MACS from Miltenyi Biotec Ltd., Bergisch Gladbach, Germany) and are available in a wide range of sizes from approximately 4.5pm-65nm in diameter. Immobilisation of MHC-peptide complexes on Dynabeads**DYNABEADS™** through Biotin-Streptavidin has previously been described (Vessey et al., 1997). Purified biotinylated protein is incubated with streptavidin-coated beads for a period of time e.g. 30 min. at 4°C after which the beads are washed to remove unbound protein. These MHC-peptide coated beads elicited an antigen-specific response when used to stimulate a cell line expressing TCR. Similarly, tetramers of TCR, or monomeric biotinylated TCR, can be immobilised on avidin/streptavidin-coated beads, or non-biotinylated TCR can be immobilised by means of anti-TCR antibody coating or by direct chemical crosslinking or by other appropriate means.

**Example 6 - Production of liposomes and drug packaging**

Lipids and other components, sterile and endotoxin tested, are commercially available from a number of sources, for instance from Sigma Chemical Company or Avanti Polar Lipids Inc., USA.

Liposomes are prepared from a mixture of vesicle-forming lipids and biotinylated vesicle-forming lipids. A variety of suitable methods exist for liposome formation. Biotinylated T cell receptor is then linked to the exterior of the liposomes via a suitable linking agent such as avidin, streptavidin or extravidin. Detectable labels and/or therapeutic agents are incorporated into the membrane itself or entrapped in the aqueous volume within the membrane.

**Example 7 - Molecular cloning of T cell receptor genes from T cell lines or T cell clones of known specificity.**

The methods and procedures for molecular cloning of TCR genes from cells is identical for all  $\alpha$  chains and for all  $\beta$  chains, respectively, and are therefore only described in this example.

A suitable number of T cells, typically 1-5 million, were lysed in Lysis Buffer from the 'mRNA Capture Kit'(Boehringer Mannheim). mRNA was isolated with kit reagents by hybridising biotinylated oligo-dT to the poly-A tails of the mRNA. The hybridised complexes were then captured by binding of biotin to 5 a PCR tube coated with streptavidin. Following immobilisation of the mRNA in the PCR tube, cDNA was generated using AMV reverse transcriptase (Stratagene) as described (Boehringer Mannheim manual for 'mRNA Capture Kit').

With the cDNA still immobilised, a poly-G tails were generated at the 3' ends 10 using the Terminal Transferase enzyme (Boehringer Mannheim). PCR reaction mix was then added, including the high fidelity thermostable polymerase *pfu* (cloned, Stratagene), which was used in order to minimise the risk of errors in the PCR products. PCR reactions were performed using a poly-C 'anchor primer' (Figure 15A) and  $\alpha$  or  $\beta$ chain specific primers (Figures 15 15B and C, respectively) annealing in the respective TCR constant regions. PCR reactions of 30 cycles of denaturation at 95°C for 1 minute, annealing at 50°C for 1 minute, and extensions at 72°C for 5 minutes were performed to amplify TCR gene fragments.

PCR products were ligated into a Bluescript sequencing vector 20 (pBluescriptPBLUESCRIPT™ II KS-, Stratagene) using the Xhol and XmaI restriction enzyme sites contained in the PCR primers (all enzymes from New England Biolabs). Following transfection of the ligation mixes in the E.coli strain XL-1BlueXL-1BLUE™, several clones for each chain were selected for DNA sequencing which was performed on an ABI 377 Prism automatic 25 sequencer using BigDyeBIGDYE™ terminators (Applied Biosystems Inc.).

**Example 8 - Molecular cloning of DNA fragments encoding the 40 amino acid coiled-coil ('leucine zipper') regions of c-jun and c-fos.**

DNA fragments encoding the 40 amino acid coiled-coil ('leucine zipper') regions of c-jun and c-fos were generated by PCR reactions using human

cDNA as template and the primers shown in Figure 16. PCR reactions were carried out in reaction buffer including cloned *pfu* polymerase (Stratagene) for 30 cycles consisting of denaturation at 95°C for 1 minute, primer annealing at 58°C for 1 minute, and extension at 72°C for 2 minutes.

5 The c-jun and c-fos fragments were ligated into pBluescriptPBLUESCRIPT™  
II KS-(Stratagene) using the unique Xhol and XmaI restriction sites to obtain  
constructs pBJ107 and pBJ108, respectively (Figure 17). The DNA  
sequences of the c-jun and c-fos fragments were verified by DNA sequencing  
performed on an ABI 377 Prism automatic sequencer using  
10 BigDyeBIGDYE™ terminators (Applied Biosystems Inc.).

The sequenced c-jun and c-fos fragments were then subcloned, using the unique XmaI and BamHI restriction sites, into the polylinker region of the T7 polymerase expression vector, pGMT7 (Studier, Rosenberg *et al.* 1990).

15 **Example 9 - Design of TCR-leucine zipper fusion proteins for the  
production of stable, soluble TCRs**

Attempts to co-refold extracellular fragments of TCR  $\alpha$  and  $\beta$  chains, truncated so that they contained the cysteine residue which *in vivo* forms a disulphide bond, produced limited success (data not shown, see Example 12 for expression methods and general methods and materials for refolding  
20 conditions). However, when the TCR  $\alpha$  and  $\beta$  chains were truncated immediately before, that is on the N-terminal side of, the cysteine residue forming the interchain disulphide bond, analytical chromatography on a SuperdexSUPERDEX™ G-75 column (Pharmacia) indicated that a small fraction of protein, approximately 1-2% of the amount used in the refolding  
25 reaction, had refolded into a complex of the expected molecular size for the truncated  $\alpha/\beta$  heterodimer (see also (Garboczi, Utz *et al.* 1996) for reference to method).

Because incorrect disulphide bond formation can cause irreversible misfolding of protein during *in vitro* refolding, the probabilities for this to

happen were sought to be minimised by mutating a cysteine residue in the TCR  $\beta$  constant region which is unpaired in the cellular TCR. The cysteine residue is substituted for a serine or an alanine residue. The synthetic DNA primers used for these mutation steps are shown in Figure 18. Co-refolding 5 of TCR  $\alpha$  and mutated  $\beta$  chains, both truncated immediately before the cysteine residue which forms the interchain disulphide bond, showed a dramatic improvement in yields of heterodimer, the protein fraction of correct molecular weight typically constituting 15-30% of total protein. However, when these soluble TCRs were stored overnight, analysis of the protein 10 showed that the fraction with a molecular weight corresponding to the heterodimeric TCR had split into two peaks of molecular weight corresponding to the monomeric TCR  $\alpha$  and  $\beta$  chains. Similar observations were made upon dilution of the soluble TCRs, indicating that  $\alpha/\beta$  chain 15 stability was low and insufficient for analyses which would require a timespan longer than a limited number of hours or dilution of the protein. In conclusion, these methods for producing soluble TCR only generated receptor with extremely limited stability.

To improve TCR  $\alpha/\beta$  chain stability, and to potentially aid heterodimer formation during refolding, the TCR chains were fused to the 'leucine zipper' 20 domains of c-jun and c-fos which are known preferentially to form heterodimers (O'Shea, Rutkowski *et al.* 1989; Schuermann, Hunter *et al.* 1991; O'Shea, Rutkowski *et al.* 1992; Glover and Harrison 1995). Two designs for the fusion TCRs were tested.

In one, the leucine zippers were fused just after, that is C-terminal to, the 25 cysteine residues forming the interchain disulphide bond in the TCR  $\alpha$  and  $\beta$  chains. As the c-jun and c-fos leucine zipper peptides are also capable of forming an interchain disulphide immediately N-terminal to the linker used (O'Shea, Rutkowski *et al.* 1989), the alignment of the two chains relative to each other, and to the interchain disulphide bond, was predicted to be 30 optimal.

In the other design, the leucine zippers were fused just before, that is N-terminal to, the cysteine residues forming the interchain disulphide bond in the TCR  $\alpha$  and  $\beta$  chains (Figure 19). Thus, in the second design the cysteine residues are omitted from the recombinant receptor.

5 In refolding experiments with TCR-zipper (TCR-z) chains of these designs, it was found that the yield of heterodimeric, soluble receptor was better when the cysteine residues forming the interchain disulphide bond were omitted from the TCR  $\alpha$  and  $\beta$  chains, as in the design shown in Figure 19.

10 **Example 10 - Construction of DNA expression vectors for TCR-leucine zipper proteins.**

This example describes the construction of expression vectors for the  $\alpha$  and  $\beta$  chains of five TCRs. The strategy and design described should be adaptable to any human or animal TCR genes. Although the five TCRs described here are all restricted by MHC class I epitopes, the methods could be identically 15 employed for the cloning and construction of expression vectors for MHC class II restricted TCRs. All vectors express protein aimed for refolding soluble TCRs according to the design shown in Figure 19, with the exception that two TCRs were expressed with a biotinylatable tag sequence at the C-terminus (see below and Figures 28, 29, and 30). The cloning strategies are 20 identical for all TCR  $\alpha$  and  $\beta$  chains, respectively.

The extent of the leader, or signal, peptide sequences of TCR  $\alpha$  and  $\beta$  chains were predicted from analyses of the sequence data obtained from plasmids containing TCR anchor PCR products (see Example 7). On this basis, 5' primers for generating PCR fragments for the expression of TCR chains 25 without leader sequences were designed (Figure 20). All 5' primers encode a methionine residue just prior to the mature TCR protein sequences in order to allow translation in *E.coli*. Silent mutations, substituting C or G bases for A or T (Figure 20), were introduced in a number of the 5' proximal codons of the genes in order to decrease the tendency for secondary mRNA structure

formations which could adversely inhibit expression levels in *E.coli* (PCT/GB 98/03235; (Gao, Tormo *et al.* 1997; Gao, Gerth *et al.* 1998).

The genes encoding the V $\alpha$ .2 and the V $\beta$ 17 chains of the human JM22 Influenza Matrix peptide-HLA-A0201 (peptide sequence GILGFVFTL)

5 restricted TCR, the human V $\alpha$ 23 and the V $\beta$ 5.1 chains of the 003 HIV-1 Gag peptide-HLA-A0201 (peptide sequence SLYNTVATL) restricted TCR, and the murine V $\alpha$ 4 and V $\beta$ 11 chains of the F5 NP peptide-H2-D<sup>b</sup> (peptide sequence ASNENMDAM) were amplified by PCR using plasmids containing TCR anchor PCR products generated as described in Example 7. The genes for  
10 the human A6 (V $\alpha$ 2.3N $\beta$ 12.3) and B7 (V $\alpha$ 17.2/V $\beta$ 12.3) TCRs which are specific the HTLV-1 Tax peptide presented by HLA-A0201 (peptide sequence LLFGYPVYV), were obtained in plasmid form (Garboczi, Utz *et al.* 1996; Ding, Smith *et al.* 1998) which were used for the generation of PCR products for the construction of expression vectors for these TCR chains. The genes  
15 for these TCRs were cloned into expression vectors that contained the sequence for a c-fos leucine zipper-biotinylatable tag fusion fragment (see Example 11).

PCR reactions were performed with cloned pfu polymerase at standard buffer conditions (Stratagene) and with 25 cycles of denaturation at 95°C for 1  
20 minute, primer annealing at 60°C for 1 minute, and extensions at 72°C for 6 minutes. The PCR products were restriction digested with the enzymes NdeI and XbaI and ligated into the pGMT7 vectors containing the *c-jun* (TCR ( $\alpha$  chains) and *c-fos* (TCR  $\beta$  chains) inserts (see Example 8).

Figures 21-30 show the sequences of the TCR-z inserts and the predicted  
25 protein sequences expressed by the pGMT7 vectors, Figure 31 shows the sequence of the A6 TCR  $\beta$  chain containing a mutation in the constant region but which did not detectably affect the folding and function of the soluble TCR (see Examples 12 and 13).

**Example 11 - Construction of DNA vectors for the expression of TCR P chains fused to a c-fos I ucin zipp r-biotinylatabl fragment.**

In order to enable soluble TCRs to be immobilised or to allow detection or attachments to the receptor, it would be useful if the protein could be

5 produced with a further functional fusion component. This could allow the soluble TCR to be derivatised, such as to be produced as multimers, or allow detection with high sensitivity, or attach other functions to the receptor/receptor complexes.

This example demonstrates the construction of expression vectors for TCR  $\beta$

10 chains onto which is engineered a fusion polypeptide which can be specifically biotinylated in *E.coli* *in vivo* or with the enzyme BirA *in vitro* (Barker and Campbell 1981; Barker and Campbell 1981; Howard, Shaw *et al.* 1985; Schatz 1993; O'Callaghan, Byford *et al.* 1999). As shown in Examples 13 and 14, these soluble TCR fusions can be expressed and refolded 15 together with a chain in an identical manner and with similar yields to the TCR  $\beta$  chain which is not fused to the 'biotinylation tag' (BT-tag). These results demonstrate that the soluble TCR described herein is likely to be suitable for expression with a multitude of different polypeptides as fusion partners.

T Cell Receptor  $\beta$ -chains were sub-cloned into a pGMT7 expression vector

20 with a biotin-tag sequence C-terminal to the *fos* leucine zipper sequence as follows:

start - TCR  $\beta$ -chain - *fos* zipper - biotin-tag - stop

The exact sequence of the ends of the constructs was as follows (see also Figure 32):

25 Linker  $\rightarrow$  I *fos* zipper  $\rightarrow$  1 BamHII  $\leftarrow$  linker  $\rightarrow$  I  $\rightarrow$  I  $\leftarrow$  biotin tag

Two approaches were used to produce soluble TCRs with the biotin tag. In the case of the human JM22 Influenza Matrix peptide-HLA-A0201 restricted

TCR, the cloned  $\beta$ -chain-*c-fos* leucine zipper fusion was modified at the 3'-end using the synthetic DNA primer shown in Figure 33 to introduce a BamH1 site instead of a HindIII site using a standard PCR reaction with *pfu* polymerase (Stratagene).

5 The original 5' primer (see Figure 20) containing an NdeI site was used as the forward primer. The PCR product produced was cloned into a modified pGMT7 vector containing the biotin-tag sequence (Figure 32) to form the construct outlined above. This plasmid is known as JMB002.

The cloned TCR specific for the HLA-A0201 restricted HTLV-I epitope

10 LLFGYPVYV, known as the A6 tax TCR (V $\alpha$ 2.3/V $\beta$ 1.2.3) was truncated using PCR with the forward and reverse primers shown in Figure 20. This TCR P-chain was cloned into the NdeI and XbaI sites of a pGMT7 vector (JMB002) containing the *c-fos*-BT fragment.

After construction of the fusion expression vectors, DNA sequencing was

15 carried out to ensure no mistakes had been introduced during the sub-cloning procedure (all sequencing was carried out in the Biochemistry Dept. DNA Sequencing Facility, Oxford University using an ABI 377 Prism sequencer and ABI BigDyeBIGDYE™ fluorescent terminators). It emerged that there were two errors in the tax TCR P-chain compared with the published  
20 sequence and upon further investigation, we discovered that these were both present in the original plasmid we had received. Since both of these errors were 3' of a unique Bsu361 site in the TCR 0-chain, this was used to clone into the (correct) JMB002 plasmid. Both versions of the tax TCR chain were expressed and refolded with a-chain and compared using  
25 BiacoreBIACORE™. Both versions of the protein specifically bound to the tax peptide -MHC class I molecules with similar apparent affinities (see Example 20). In subsequent experiments, only the correct version of the P-chain was used.

**Example 12 - Expression of TCR chains in *E.coli* and purification of inclusion bodies**

TCR  $\alpha$  and  $\beta$  chains were expressed separately in the *E.coli* strain BL21DE3pLysS under the control of the vector pGMT7 in TYP media, using

5 0.5mM IPTG to induce protein production when the optical density (OD) at 600nm reached between 0.2 and 0.6. Induction was allowed to continue overnight and the bacteria were harvested by centrifugation at 4000 rpm in a Beckman J-6 $\beta$  centrifuge.

Bacterial cell pellets were then resuspended in 'lysis buffer' (10 mM Tris pH 10 8.1, 10 mM EDTA, 150 mM NaCl, 2 mM DTT, 10% glycerol). The mixture was cooled on ice and the following were added: 20  $\mu$ g/ml lysozyme, 10 mM MgCl<sub>2</sub>, and 20  $\mu$ g/ml DNase 1, followed by incubation on ice for a minimum of an hour.

The mixture was then sonicated using a 12mM probe sonicator (Milsonix 15 XL2020) at full power for 5 bursts of 30s with intervals of 30s to allow the mixture to cool down. Temperature was maintained during this procedure by use of an ice-water mixture. The mixture was then diluted with 5 volumes of 'Triton wash buffer' (50 mM Tris pH 8.1, 0.5% Triton<sup>TM</sup> X-100, 100 mM NaCl, 0.1% sodium azide, 10 mM EDTA, 2 mM DTT). After incubation 20 on ice for a minimum of 1 hour, the mixture was then centrifuged at 3,500 rpm in a Beckman GS-6R centrifuge and the supernatant was discarded. The pellet was resuspended in 'Resuspension buffer' (50 mM Tris pH 8.1, 100 mM NaCl, 10 mM EDTA, 2 mM DTT) using a small plastic disposable pipette. The mixture was then centrifuged at 8,000 rpm in a Beckman J2-21 centrifuge 25 and the supernatant discarded. The pellet was then resuspended in 'Guanidine buffer' (50 mM Tris pH 8.1, 6.0 M Guanidine-HCl, 100 mM NaCl, 10 mM EDTA, 10 mM DTT) using a hand-operated homogeniser. After low-speed centrifugation to remove insoluble material, the supernatant was aliquotted and stored at -70°C. An approximate yield of 100 mg per litre of 30 bacterial culture was routinely obtained.

SDS-PAGE analysis of the purified inclusion body preparation was achieved by diluting 2  $\mu$ l of inclusion body preparation in Guanidine buffer with SDS-PAGE sample buffer followed by heating to 100°C for 2 minutes. Samples were loaded onto the gel while still warm to prevent the Guanidine/SDS

5 mixture from precipitating during loading. Inclusion body protein purified in this way was judged to be approximately 90% pure by Coomassie staining of SDS-PAGE performed in this way (see Figure 34).

**Example 13 - Refolding and purification of the TCR $\zeta$  heterodimer.**

Urea-solubilised proteins in equal proportions were further denatured in

10 'guanidine buffer' (6 M guanidine-HCl, 10 mM sodium acetate pH 5.5, 10 mM EDTA, 2 mM DTT) at 37°C. The mixture of proteins was injected into ice-cold refolding buffer (100 mM Tris pH 8.1, 0.4 M L-Arginine-HCl, 5.0 M Urea, 5 mM reduced glutathione, 0.5 mM oxidised glutathione) at a total protein concentration of 60 mg/L ensuring rapid mixing. After incubation on ice for at

15 least 5 hours to allow refolding, the mixture was dialysed against 10 volumes of demineralised water for 24 hours and then against 10 volumes of 10 mM Tris pH 8.1 for 24 hours.

The dialysed refolded protein was then filtered to remove aggregated protein (produced as a by-product during the refolding) through a 0.45 $\mu$  nitro-cellulose membrane (Whatman). Purification of the biotin-tagged soluble TCR was then performed by loading onto a POROSPOROS<sup>TM</sup> 20HQ column run on a BiocadBIOCAD<sup>TM</sup> Sprint system. Approximately 500 ml of refolded protein solution could be loaded per run and elution of the protein was achieved by a gradient of sodium chloride in Bis-Tris-Propane buffer pH 8.0.

25 The protein eluted at approximately 100 mM sodium chloride and the relevant fractions were immediately chilled on ice and protease inhibitor cocktail was added. Fractions were analysed by Coomassie-stained SDS-PAGE.

**Example 14 - Refolding and purification of the TCR $\zeta$  heterodimer with a biotinylatable  $\beta$ chain.**

Biotin-tagged TCR  $\beta$ -chains were mixed with an equal quantity of  $\alpha$ -chain expressed and purified as for the soluble T cell receptor. Heterodimeric TCRz  $\beta$ -BT was refolded according to identical procedures as described in Example 13 for TCRz (see Figure 37).

5 **Example 15 - Biotinylation of biotin-tagged soluble TCRz-BT**

Protein-containing fractions were concentrated to 2.5 ml using 10K-cut-off centrifugal concentrators (Ultrafree, Millipore). Buffer was exchanged using PD-1 0 desalting columns equilibrated with 10 mM Tris pH 8.1, 5mM NaCl, further protease inhibitor cocktail was added, and the protein was

10 concentrated to ~1 ml using centrifugal concentrators again. To this 1 ml of biotin-tagged soluble TCR the following were added: 7.5 mM MgCl<sub>2</sub>, 5 mM ATP (pH 8.0), 1 mM biotin, 2.5  $\mu$ g/ml BirA biotinylation enzyme. The biotinylation reaction was then allowed to proceed at room temperature (20-25°C) overnight.

15 Enzymatically biotinylated soluble TCR was then separated from residual unreacted biotin by gel filtration on a ~~Superdex~~**SUPERDEX™** 200 HR column (Pharmacia) run on a ~~Pharmacia~~**FPLCPHARMACIA FPLC™** system (see Figure 38). The column was equilibrated with PBS and 1 ml fractions were collected which were immediately chilled on ice and protected with protease 20 inhibitor cocktail again. Protein concentration was estimated using a Coomassie-binding assay (Pierce) and the biotinylated protein was then stored at 4°C for up to a month or at -20°C for longer periods.

The efficacy of the biotinylation reaction was checked using Western blotting of the biotinylated protein. An SDS-PAGE gel was run using the methods

25 described before, but instead of staining, the gel was blotted onto a PVDF membrane (Bio-Rad) using a ~~SemiPher~~**SEMIPHOR™**-semi-dry electroblotting apparatus (Hoefer). The blotting stack comprised of 6 layers of filter paper (Whatman 4M) cut to the size of the gel and soaked in transfer buffer (25 mM Tris base, 150 mM glycine) followed by the PVDF membrane which was pre-

wetted with methanol and then soaked in transfer buffer, followed by the gel which was gently agitated in transfer buffer for 5 minutes, followed by 6 more layers of soaked filter paper. The stack was gently compressed using a test-tube to roll out any air-bubbles and approximately 10 ml of additional transfer

5 buffer was added to aid conduction. The cathode was placed on top of the stack and current was passed through the apparatus at a constant current of 50 mA for 1 hour. The membrane was then incubated in a 2 % solution of gelatin (Bio-Rad) in PBS-T buffer (PBS + 0.05% Tween-20) for > 1 hour at room temperature with gentle agitation. Overnight incubations also included

10 0.01% sodium azide to inhibit bacterial growth. The membrane was washed with several (4-5) changes of PBS-T followed by staining with avidin-HRP conjugate (Sigma) diluted 1:1000 in a 1% solution of gelatin in PBS-T for >30 minutes at room temperature with gentle agitation. The membrane was then washed with several (4-5) changes of PBS-T prior to detection with Opti-4CN

15 (Bio-Rad). This is a reagent with reacts in the presence of HRP to form an insoluble blue dye which stains the membrane in the place where relevant protein is present as indicated by the presence of bound HRP. When avidin-HRP conjugate is used to stain, this therefore indicates the presence of a biotin-containing protein.

20 Figure 39 shows a blot performed in such a way on several biotinylated TCRs. The standards run on this blot were biotinylated broad range molecular weight markers (Bio-Rad). The blot clearly shows that a high level of biotinylation of the TCRs containing the biotinylation tag which have been reacted with the BirA enzyme

25 **Example 16 - Production of biotinylated soluble MHC-peptide complexes**

Biotinylated soluble MHC-peptide complexes can be produced as described in Example 2.

**Example 17 - Assay for specific binding between soluble TCR and MHC-flu-peptide**

The soluble TCR molecule, JM22z, is specific for HLA-A2 MHC molecules presenting an immuno dominant antigen consisting of amino acid residues 58-66 (GILGFVFTL) of the influenza matrix protein. The cloning, expression, and purification of JM22z is described in Examples 7, 10, 11 and 13 and in

5 Figures 35 and 36. The interactions between JM22z and its ligand/ MHC complex (HLA-A2-flu) or an irrelevant HLA-A2 peptide combination, the production of which is described in Example 13, were analysed on a BiacoreBIACORE 2000™ surface plasmon resonance (SPR) biosensor. SPR measures changes in refractive index expressed in response units (RU) near

10 a sensor surface within a small flow cell, a principle that can be used to detect receptor ligand interactions and to analyse their affinity and kinetic parameters. The probe flow cells were prepared by immobilising the individual HLA-A2-peptide complexes in separate flow cells via binding between the biotin cross linked onto  $\beta$ 2m and streptavidin which had been

15 chemically cross linked to the activated surface of the flow cells. The assay was then performed by passing JM22z over the surfaces of the different flow cells at a constant flow rate, measuring the SPR response in doing so. Initially, the specificity of the interaction was verified by passing 28  $\mu$ M JM22z at a constant flow rate of 5  $\mu$ l min<sup>-1</sup> over three different surfaces; one coated

20 with 2800 RU of HLA-A2-flu, the second coated with 4200 RU of HLA-A2 folded with an irrelevant peptide from HIV reverse transcriptase (HLA-A2-pol: ILKEPVHGV), and the third coated with 4300 RU of CD5 (Fig. 40a inset). Injections of soluble JM22z at constant flow rate and different concentrations over HLA-A2-pol were used to define the background resonance (Fig. 40a).

25 The values of these control measurements were subtracted from the values obtained with HLA-A2-flu (Fig. 40b) and used to calculate binding affinities expressed as the dissociation constant, Kd (Fig. 40c). The Kd of JM22z and the relevant MHC molecule was determined to be 15  $\pm$  4- $\mu$ M (n=7) at 37 °C and 6.6  $\pm$  2  $\mu$ M (n=14) at 25 °C. Determination using immobilised TCR in the

30 probe flow cell and soluble MHC-peptide complex gave a similar Kd of 5.6  $\pm$  4  $\mu$ M(n=3) at 25 °C. The on-rate of the interaction was determined to be

between  $6.7 \times 10^4$  and  $6.9 \times 10^4 \text{ M}^{-1}\text{s}^{-1}$  at  $37^\circ\text{C}$  while the off-rate was  $1.1 \text{ s}^{-1}$  (Willcox, Gao *et al.* 1999).

**Example 18 - Assay for specific binding between soluble murine TCR and murine MHC H2-D<sup>b</sup>-NP**

5 In this experiment, we used a murine TCR, F5, specific for a peptide derived from the influenza virus nucleoprotein (aa.366-374: ASNENIVIDAM) presented by the murine H2-D<sup>b</sup> MHC molecule (H2-D<sup>b</sup>-NP). The MHC heavy chain gene used was slightly modified in the sense that it encoded only amino acids 1-280 of the native protein plus a 13-amino acid 10 sequence recognised by the BirA enzyme. The resulting protein can be biotinylated enzymatically (Schatz 1993; O'Callaghan, Byford *et al.* 1999). SPR analysis on the Biacore**BIACORE** 2000<sup>TM</sup> SPR biosensor using this soluble TCR specific for immobilised H2-D<sup>b</sup>-NP showed that it bound specifically to the ligand MHC-peptide combination (data not shown).

15 **Example 19 - Comparison of binding of biotinylated soluble tax-TCR with biotinylated soluble mutant tax-TCR**

Biotinylated soluble tax-TCRs were prepared as in Examples 12-14 and Biacore**BIACORE** 2000<sup>TM</sup> analysis was performed as in Example 17 using biotinylated pMHC complexes refolded with either influenza matrix peptide 20 (GILGVFTL) or HTLV tax 11-19 peptide (LLFGYPVYV). Biotinylated soluble TCRs were flowed over all cells at  $5 \mu\text{L}/\text{minute}$  for a total of 1 minute. Figure 41 shows the binding of firstly the biotinylated soluble tax-TCR and then the biotinylated soluble mutant tax-TCR to HTLV tax 11-19 S21-peptide-MHC complex (A). Neither the wild-type nor the mutant tax-TCR showed binding to 25 either the influenza matrix peptide-MHC complex (B/C) or OX68 monoclonal antibody control (D). Therefore, we conclude that both the wild-type and the mutant biotinylated soluble TCRs clearly bind effectively and specifically to the tax-pMHC complex and show very little difference in the degree of binding.

**Example 20 - Analysis of simultaneous TCR- and CD8 co-receptor binding to immobilised MHC peptide complex**

CD8 and CD4 are surface glycoproteins believed to function as co-receptors for TCRs by binding simultaneously to the same MHC molecules as the TCR.

5 CD8 is characteristic for cytotoxic T cells and binds to MHC class I molecules while CD4 is expressed on T cells of the helper lineage and binds MHC class II molecules. CD8 is a dimer consisting of either two identical  $\alpha$ -chains or of an  $\alpha$  and a  $\beta$ -chain. The homodimeric  $\alpha\alpha$ -CD8 molecule was produced as described (PCT/GB98/03235; (Gao, Tormo *et al.* 1997; Gao, Gerth *et al.* 10 1998). In this example, we describe the simultaneous binding of soluble TCR and CD8 molecules to immobilised HLA-A2-flu complex. As seen in Figure 42A, the binding response was simply additive. Subtracting the values of the TCR response (open circles) from the values of the combined response (closed circles) gave values (open squares) very close to the value 15 of the response of 120  $\mu$ M CD8 alone (open triangles). Figure 42B shows that the kinetics of the TCR-MHC-peptide interaction was unaffected by simultaneous CD8 binding. The observed additive binding indicate that TCR and CD8 bind the MHC peptide complex at separate interfaces. The example also illustrates that in some cases specific binding of one molecule will not 20 influence specific binding of another molecule, a situation most likely to be different for other combinations of molecules.

**Example 21 - Formation of TCR tetramers from biotinylated soluble TCR**

Formation of TCR tetramers was achieved using avidin or streptavidin or their derivatives. Avidin (from hen egg) has an unusually high isoelectric point 25 resulting in high positive charge at neutral pH which causes non-specific binding to many other proteins and surfaces. It is therefore often commercially modified to lower the isoelectric point so that it behaves more like streptavidin (from bacterial source). In this form, it is known as Extravidin (Sigma) or Neutravidin (Molecular Probes). Either of these, or streptavidin

may be modified to contain a label such as a fluorescent tag for detection using FACS scanning.

TCR tetramers were formed using a final extravidin/streptavidin concentration of 1/4 of the total biotinylated soluble TCR concentration.

- 5    Extravidin/streptavidin was added on ice in aliquots so that if the concentration was not quite accurate, most of the extravidin/streptavidin would still be saturated with TCR. The TCR tetramers were analysed by size exclusion chromatography on a Superdex**SUPERDEX™** 200 HR column (Pharmacia) - Figures 43 and 44. Linking of TCR to avidin was confirmed by
- 10   running control samples of unlinked TCR and extravidin/streptavidin separately. The TCR tetramer eluted from the column at a retention volume corresponding to higher molecular weight. For unmodified extravidin, it was possible to determine the approximate molecular weight of the TCR tetramers produced (by comparison with standard proteins of known molecular weight)
- 15   to be ~285,000 compared to a calculated molecular weight for a complete TCR tetramer of 305,000.

**Example 22 - Analysis of binding of biotinylated monomeric TCR and TCR tetramers to MHC peptide**

Peptide-MHC complexes were prepared as in Example 16 using the influenza matrix peptide (GILGFVFTL) or the HTLV tax peptide (LLFGYPVYV), recombinant HLA-A2 heavy chain and recombinant chemically biotinylated  $\beta$ -2-microglobulin. A Biacore**BIACORE 2000™** SPR biosensor was used to measure molecular interactions between TCRs, TCR-tetramers and pMHC complexes. Biotinylated pMHC complexes were immobilised to streptavidin conjugated to the CM-5 chip surface by amine coupling. OX68, a biotinylated monoclonal antibody, provided by Dr. P. Anton van der Merwe from Sir William Dunn School of Pathology, was used as a non-specific control protein in one of the cells.

Following pMHC complex immobilisation, residual biotin-binding sites were saturated with 10 mM biotin. This is necessary to prevent biotinylated TCRs from binding to the streptavidin-coated chip via their biotinylation rather than specifically via the TCR-pMHC interaction. Soluble biotinylated TCRs were 5 then flowed over the chip at a concentration of approximately 1 mg/ml and TCR tetramers were flowed over at a concentration of approximately 50  $\mu$ g/ml.

Figure 45 shows the binding of soluble biotinylated flu-TCR and flu-TCR tetramers to pMHC complexes, figure 46 shows the binding of soluble 10 biotinylated tax-TCR and tax-TCR tetramers to the same pMHC complexes. Both the biotinylated sTCRs and the TCR tetramers show complete specificity, binding strongly to their specific peptide-MHC complex but not at all to the non-specific peptide MHC complex. The increase in the affinity caused by multimerisation of the sTCR can be seen in the respective off-rates 15 for the sTCR and the TCR tetramer for both TCRs. The off rate for both TCRs is increased from several seconds to several hours (exact measurement of off-rates was not possible due to re-binding effects).

Some more permanent binding of biotinylated soluble TCR was observed in both cases which is caused by the presence of aggregated protein in the 20 preparations. In both cases, this level of strong binding was very low compared with the TCR tetramers bearing in mind that the total amount of TCR tetramer injected over the flow cell was approximately 1/4 of the amount of biotinylated soluble TCR injected (25  $\mu$ l x 0.05 mg/ml compared to 5  $\mu$ l x 1 mg/ml).

25 **Example 23 - Staining of antigen-presenting cells with TCR tetramers**

Cell-staining experiments were performed on a B-cell line called T2 which is homozygous for HLA-A2 and does not process peptide antigens resulting in the presence of unfilled MHC class I molecules on the cell surface which can be filled with a single type of external peptide. Cells were grown in R-10

medium at 37°C and 5% CO<sub>2</sub> atmosphere. Approximately 2 million cells were taken and washed twice in RPMI medium (centrifugation was 1,500 rpm for 5 minutes), peptide was added at varying concentrations in 10% DMSO in RPMI. Typically, concentrations of 0, 10<sup>-4</sup>, 10<sup>-5</sup>, and 10-6 M of influenza matrix peptide (sequence: GILGFVFTQ and tax peptide (sequence: LLFGYPVYV) were used. Cells were pulsed for 1 hour at 37°C to allow peptide to bind to the MHC class I molecules on the cell surface. Cells were then washed twice with RPMI medium to remove excess peptide.

Peptide pulsed cells were stained with TCR tetramer at room temperature with 1-10 µg of TCR tetramer labelled with either FITC or RPE fluorescent marker. Staining was allowed to continue for 30 minutes and cells were then washed once with ice-cold RPMI followed by fixing with 3% formaldehyde in PBS solution. Fixed, stained cells were then stored at 4°C in the dark for up to a week prior to FACS analysis.

FACS analysis was performed using a Becton-Dickinson FACS scanner and data was recorded and analysed using 'Cellquest<sup>CELLQUEST™</sup>' software. Figure 47 shows the specific binding of TCR tetramers made with either the flu matrix TCR or the tax TCR to their specific peptides. Background and crossreactivity were low. Interestingly, the tax TCR tetramer seems to bind better to its peptide than flu matrix TCR tetramer does to its peptide, although this may be an effect of varying affinities of the peptide for the MHC class I molecules during the peptide pulsing.

Another variety of cells were also stained using TCR tetramers, .45 cells, which are a normal B-cell line heterozygous for HLA-A2. Cells were prepared and peptide pulsed, labelled and FACS scanned exactly as for T2 cells. Figure 48 shows the results of TCR tetramer labelling of peptide pulsed .45 cells. The staining of the cells is noticeably lower than that for T2 cells, which is as expected given that the .45 cells are heterozygous for HLA-A2 whereas the T2 cells are homozygous. In addition to this effect, it is possible that

because the MHC class I complexes on the surface of .45 cells are initially loaded with peptide, whereas in the case of the T2 cells the complexes are initially empty, there may be a greater efficiency of peptide loading onto the surface of T2 cells compared with other HLA-A2 positive cells.

5 **Example 24 - Preparation of, and staining with, TCR-coated latex beads**

In order to improve the sensitivity of the TCR staining for antigen, TCR-coated beads labelled with fluorescent marker were made. The fluorescently labelled, neutravidin-coated beads were purchased from Molecular Probes. The coating of the beads with biotinylated soluble TCR was performed by co-  
10 incubation at 4°C with a saturating concentration of TCR to ensure that the maximal number of binding sites on the beads were occupied with TCR. The beads were then used to label peptide-pulsed antigen-presenting cells a similar way to that described for TCR tetramers except that blocking reagents were included to reduce the background level. This strategy was not entirely  
15 successful as evidenced by the high amount of staining for non-pulsed cells and for cells pulsed with irrelevant peptide. However, a substantial amount of specific labelling was also observed over the background level of staining (Figure 49). Interestingly, some labelling of tax peptide pulsed T2 cells with tax TCR-coated beads was observed. This labelling is at an order of  
20 magnitude lower peptide concentration than is possible to detect using TCR tetramers indicating that higher multimerisation of the TCR will enable detection and binding to lower levels of presented antigen.

**References:**

**Ahmad, I., and Allen, T. M. (1992).** Cancer Res 52, 4817-20.

**Ahmad, I., Longenecker, et al. (1993).** Cancer Res 53, 1484-8

**Alifantis, I., O. Azogui, et al. (1998).** Immunity 9(5): 649-55.

5 **Allen, T. M. (1997).** Drugs 54 Suppl 4, 8-14.

**Allen, T. M. (1994).** Trends Pharmacol Sci 15, 215-20.

**Allen, T. M., Ahmad, et al. (1995).** Biochem Soc Trans 23, 1073-9.

**Allen, T. M., Brandeis, E., et al. (1995).** [published erratum appears in Biochim Biophys Acta 1995 Dec 13;1240(2):285]. Biochim Biophys Acta

10 **1237, 99-108.**

**Allen, T. M., Newman, et al. (1995).** Int J Cancer 62, 199-204.

**Altamirano, M. M., C. Garcia, et al. (1999).** Nature Biotechnology 17: 187-191.

**Altamirano, M. M., R. Golbik, et al. (1997).** Proc Natl Acad Sci U S A 94(8):

15 **3576-8.**

**Altman, J. D., Moss, P. A. H., et al. (1996).** Science 274, 94-6.

**Amati, B., S. Dalton, et al. (1992).** Nature 359(6394): 423-6.

**Bangham, A. D., Standish, M. M., et al. (1965).** J Mol Biol 13, 238-52.

**Barenholz, Y., Amselem, S., et al. (1979).** FEBS Left 99, 210-4.

20 **Barker, D. F., and Campbell, A. M. (1981).** J Mol Biol 146, 451-67.

**Barker, D. F., and Campbell, A. M. (1981).** J Mol Biol 146, 469-92.

**Bentley, G. A., Boulot, G., et al. (1995).** Science 267, 1984-7 ISSN: 0036-8075.

**Bjorkman, P. J., Strominger, J. L., et al. (1985).** J. Mol. Biol 186(I) 205-10.

25 **ISSN: 0022-2836.**

**Boic** , J. A., G. R. Dieckmann, et al. (1996). *Biochemistry* 35(46): 14480-5.

**Boulot**, G., Bentley, G. A., et al. (1994). *J Mol Biol* 235, 795-7 ISSN: 0022-2836.

**Brocke**, T., Peter, A., et al. (1993). *Eur J Immunol* 23, 1435-9 ISSN: 0014-5 2980.

**Brunner**, J., Skrabal, P., et al. (1976). *Biochim Biophys Acta* 455, 322-31.

**Buday**, L. and J. Downward (1993). *Cell* 73(3): 611-20.

**Calaman**, S. D., Carson, G. R., et al. (1993). *J Immunol Methods* 164, 233-44 ISSN: 0022-1759.

10 **Callan**, M. F., Tan, L., et al. (1998). *J Exp Med* 187, 1395-402.

**Chang**, H. C., Bao, Z., et al. (1994). *Proc Natl Acad Sci U S A* 91, 11408-12.

**Chao**, H., M. E. Houston, Jr., et al. (1996). *Biochemistry* 35(37): 12175-85.

**Chen**, H., and Langer, R. (1997). *Pharm Res* 14, 537-40.

**Chen**, H., Torchilin, V., et al. (1996). *Pharm Res* 13, 1378-83.

15 **Chicz**, R. M., Urban, R. G., et al. (1993). *J Exp Med* 178, 27-47.

**Chevray**, P. M. and D. Nathans (1992). *Proc Natl Acad Sci U S A* 89(13): 5789-93.

**Cohen**, S., Alonso, M. J., et al. (1994). *Int J Technol Assess Health Care* 10,121-30.

20 **Cohen**, S., Bernstein, H., et al. (1991). *Proc Natl Acad Sci U S A* 88, 10440-4.

**Corr**, M., Slanetz, A. E., et al. 1994). *Science* 265, 946-9.

**Davis**, M. M., J. J. Boniface, et al. (1998). *Annu. Rev. Immunol.* 16: 523-544.

**de Kruif**, J. and T. Logtenberg (1996). *J Biol Chem* 271(13): 7630-4.

25 **Ding**, Y. H., Smith, K. J., et al. (1998). *Immunity* 8, 403-11.

**Dunbar**, P. R., Ogg, G. S., et al. (1998). *Curr Biol* 8, 413-6.

**Edelman**, E. R., Brown, L., and Langer, R. (1996). *J Pharm Sci* 85, 1271-5.

**Eilat**, D., Kikuchi, G. E., et al. (1992). *Proc Natl Acad Sci U S A* 89, 6871-5  
Issn: 0027-8424.

**Engelhard**, V. H. (1994). *Annu Rev Immunol* 12, 181-207.

5 **Engelhard**, V. H., Appella, E., et al. (1993). *Chem Immunol* 57, 39-62.

**Fields**, B. A., Malchiodi, E. L., et al. (1996). *Nature* 384, 188-92 Issn: 0028-0836.

**Gao**, G. F., Gerth, U. C., et al. (1998). *Prot. Sci.* 7, 1245-49.

**Gao**, G. F., Tormo, J., et al. (1997). *Nature* 387, 630-4.

10 **Garboczi**, D. N., Ghosh, P., et al. (1996). *Nature* 384, 134-41 Issn: 0028-0836.

**Garboczi**, D. N., Hung, D. T., et al. (1992). *Proc Natl Acad Sci U S A* 89, 3429-33 Issn: 0027-8424.

15 **Garboczi**, D. N., Madden, D. R., et al. (1994). *J Mol Biol* 239, 581-7 Issn: 0022-2836.

**Garboczi**, D. N., Utz, U., et al. (1996). *J Immunol* 157, 5403-10 Issn: 0022-1767.

**Garcia**, K. C., Degano, M., et al. (1996). *Science* 274, 209-19 Issn: 0036-8075.

20 **Garcia**, K. C., Scott, C. A., et al. (1996). *Nature* 384, 577-81 Issn: 0028-0836.

**Glover**, J. N. and S. C. Harrison (1995). *Nature* 373(6511): 257-61.

**Golden**, A., Khandekar, S. S., et al. (1997). *J Immunol Methods* 206, 163-9.

**Greenfield**, N. J., G. T. Montelione, et al. (1998). *Biochemistry* 37(21): 7834-43.

25 **Gregoire**, C., Malissen, B., et al. (1996). *Eur J Immunol* 26, 2410-6 Issn: 0014-2980.

**Gregoir** , C., Rebai, N., et al. (1991). *Proc Natl Acad Sci U S A* **88**, 8077-81  
Issn: 0027-8424.

**Hilyard** et al. (1994) *Proc. Naff. Acad. Sci.* **91**: 9057-9061.

**Howard**, P. K., J. Shaw, et al. (1985). *Gene* **35**(3): 321-31.

5 **Hansen**, C. B., Kao, G. Y., et al. (1995). *Biochim Biophys Acta* **1239**, 133-44.

**Hu**, J. C., N. E. Newell, et al. (1993). *Protein Sci* **2**(7): 1072-84.

**Huang**, C. (1969). *Biochemistry* **8**, 344-52.

**Huczko**, E. L., Bodnar, W. M., et al. (1993). *J Immunol* **151**, 2572-87.

**Hunt**, D. F., Michel, H., et al. (1992). *Science* **256**, 1817-20 Issn: 0036-8075.

10 **Ishii**, Y., Nakano, T., et al. (1995). *J Immunol Methods* **186**, 27-36 Issn: 0022-1759.

**Konigsberg**, P. J., Godtel, R., et al. (1998). *Biochim Biophys Acta* **1370**, 243-51.

**Kouzarides**, T. and E. Ziff (1989). *Nature* **340**(6234): 568-71.

15 **Landschulz**, W. H., P. F. Johnson, et al. (1988). *Science* **240**(4860): 1759-64.

**Langer**, R. (1998). *Nature* **392**, 5-10.

**Lowenstein**, E. J., R. J. Daly, et al. (1992). *Cell* **70**(3): 431-42.

**Lumb**, K. J. and P. S. Kim (1995). *Biochemistry* **34**(27): 8642-8.

20 **Madden**, D. R., Garboczi, D. N., et al. (1993). [published erratum appears in *Cell* 1994 Jan 28;76(2):following 410]. *Cell* **75**, 693-708 Issn: 0092-8674.

**Matsui**, K., J. J. Boniface, et al. (1994). *Proc Natl Acad Sci USA* **91**(26): 12862-6 Issn: 0027-8424.

**Mayer**, L. D., Hope, M. J., Cullis, P. R., et al. (1985). *Biochim Biophys Acta* **817**, 193-6.

**McHeyzer Williams, M. G., Altman, J. D., et al. (1996). Immunol Rev 150, 5-21.**

**McKnight, S. L. (1991). Sci Am 264(4): 54-64.**

**McMichael, A. J., and O'Callaghan, C. A. (1998). J Exp Med 187, 1367-71.**

5 **Moss et al.. (1991) Proc. Natl. Acad. Sci. USA 88: 8987-8990 ISSN: 0027-8424.**

**Murali Krishna, K., Altman, J. D., et al. (1998). Immunity 8, 177-87.**

**Nautiyal, S., D. N. Woolfson, et al. (1995). Biochemistry 34(37): 11645-51.**

10 **Necker, A., Rebai, N., et al. (1991). Eur J Immunol 21, 3035-40 ISSN: 0014-2980.**

**Ogg, G. S., Jin, X., et al. (1998). Science 279, 2103-6.**

**Okada, J., Cohen, S., and Langer, R. (1995). Pharm Res 12, 576-82.**

**O'Callaghan, C. A., M. F. Byford, et al. (1999). Anal Biochem 266(1): 9-15.**

**O'Shea, E. K., R. Rutkowski, et al. (1992). Cell 68(4): 699-708.**

15 **O'Shea, E.K., Lumb, K.J. and Kim, P.S. (1993) Curr. Biol. 3: 658-667.**

**O'Shea, E.K., Rutkowski, R., et al. (1989) Science 245: 646-648.**

**Plaksin, D., Polakova, K., et al. (1997). J Immunol 158, 2218-27.**

**Rabinowitz, J. D., C. Beeson, et al. (1996). Proc Natl Acad Sci USA 93(4): 1401-5 ISSN: 0027-8424.**

20 **Ramiro, A. R., C. Trigueros, et al. (1996). J Exp Med 184(2): 519-30 ISSN: 0022-1007.**

**Reid, S. W., McAdam, S., et al. (1996). J Exp Med 184, 2279-86.**

**Reid, S. W., Smith, K. J., et al. (1996). FEBS Left 383, 119-23.**

**Riley, L. G., G. B. Ralston, et al. (1996). [published erratum appears in Protein Eng 1996 Sep;9(9):831]." Protein Eng 9(2): 223-30.**

**Romagne, F., Peyrat, M. A., et al. (1996).** *J Immunol Methods* 189, 25-36  
Issn: 0022-1759.

**Saint Ruf, C., K. Ungewiss, et al. (1994).** *Science* 266(5188): 1208-12 Issn:  
0036-8075.

5 **Schatz, P. J. (1993).** *Biotechnology N Y* 11, 1138-43.

**Schlessinger, J. (1994).** *Curr Opin Genet Dev* 4(1): 25-30.

**Schlueter, C. J., Schodin, B. A., et al. (1996).** *J Mol Biol* 256, 859-69.

**Schuermann, M., J. B. Hunter, et al. (1991).** *Nucleic Acids Res* 19(4): 739-46.

10 **Smith, K. J., Reid, S. W., et al. (1996).** *Immunity* 4, 215-28 Issn: 1074-7613.

**Smith, K. J., Reid, S. W., et al. (1996).** *Immunity* 4, 203-13 Issn: 1074-7613.

**Studier, F. W., Rosenberg, A. H., et al. (1990).** *Methods Enzymol* 185, 60-89  
Issn: 0076-6879.

15 **Szoka, F, Jr., and Papahadjopoulos, D. (1978).** *Proc Natl Acad Sci USA* 75,  
4194-8.

**Tan, L. S., and Gregoriadis, G. (1990).** *Ann Acad Med Singapore* 19, 827-30.

**Uster, P. S., Allen, T. M., et al. (1996).** *FEBS Left* 386, 243-6.

**Vessey, S. J. R., Barouch, D. H., et al. (1997).** *Eur J Immunol* 27, 879-885.

**von Boehmer, H., I. Aifantis, et al. (1998).** *Immunol Rev* 165: 111-9.

20 **Weber, S., Traunecker, A., et al. (1992).** *Nature* 356, 793-6 Issn: 0028-0836.

**Willcox, B. E., G. F. Gao, et al. (1999).** *Immunity* 10: 357-65.

**Wilson, A. and H. R. MacDonald (1995).** *Int Immunol* 7(10): 1659-64 Issn:  
0953-8178.

**Wurch, A., J. Biro, et al. (1998).** *J Exp Med* 188(g): 1669-78.

25 **Wyer, J. R., B. E. Willcox, et al. (1999).** *Immunity* 10: 219-225.

**Zalipsky, S., Hansen, C. B., et al. (1996).** *J Pharm Sci* 85, 133-7.

Zhang, Z., A. Murphy, et al. (1999). Curr Biol 9(8): 417-20.

## CLAIMS

1. A synthetic multivalent T cell receptor (TCR) complex for binding to a MHC-peptide complex, which TCR complex comprises a plurality of T cell receptors specific for the MHC-peptide complex.
- 5 2. The TCR complex according to claim 1, wherein the T cell receptors are  $\alpha\beta$  T cell receptors having an  $\alpha$  chain and a  $\beta$  chain.
3. The TCR complex according to claim 2, wherein the  $\alpha$  chain and  $\beta$  chain are soluble forms of T cell receptor  $\alpha$  and  $\beta$  chains.
- 10 4. The TCR complex according to any preceding claim, wherein the T cell receptors are in the form of multimers of two or more T cell receptors.
5. The TCR complex according to claim 4, wherein the multimer is a trimer or a tetramer.
6. The TCR complex according to any preceding claim, wherein the T cell receptors are associated with one another via a linker molecule.
- 15 7. The TCR complex according to claim 6, wherein the linker molecule is a multivalent attachment molecule such as avidin, streptavidin or extravidin.
8. The TCR complex according to claim 7, wherein at least one of the T cell receptor  $\alpha$  or  $\beta$  chains is derived from a fusion protein comprising an amino acid recognition sequence for a modifying enzyme such as biotin.
- 20 9. The TCR complex according to claim 8, wherein the T cell receptors are biotinylated.
10. The TCR complex according to any preceding claim, comprising a multimerised recombinant T cell receptor heterodimer having enhanced binding capability compared to a non-multimeric T cell receptor heterodimer.
- 25 11. A multivalent TCR complex comprising a multimerised recombinant T cell receptor heterodimer having enhanced binding capability compared to a non-multimeric T cell receptor heterodimer.
12. The TCR complex according to any preceding claim, wherein the T cell receptor is a refolded recombinant T cell receptor which comprises:
- 30 i) a recombinant T cell receptor ( $\alpha$  or  $\gamma$  chain extracellular domain having a first heterologous C-terminal dimerisation peptide; and
- ii) a recombinant T cell receptor  $\beta$  or  $\delta$  chain extracellular domain having a second C-terminal dimerisation peptide which is specifically

heterodimerised with the first dimerisation peptide to form a heterodimerisation domain.

1.13. The TCR complex according to claim 12, wherein a disulphide bond present in native T cell receptors between the  $\alpha$  and  $\beta$  or  $\gamma$  and  $\delta$  chains adjacent to the cytoplasmic domain, is absent from the recombinant T cell receptor.

5 14. The TCR complex according to claim 12 or claim 13, wherein the heterodimerisation domain is a coiled coil domain.

10 15. The TCR complex according to claim 14, wherein the dimerisation peptides are c-jun and c-fos dimerisation peptides.

16. The TCR complex according to any one of claims 12 to 15, comprising a flexible linker located between the T cell receptor chains and the heterodimerisation peptides.

15 17. The TCR complex according to any one of claims 10 to 16, wherein the T cell receptor is expressed in an E.coli expression system.

18. The TCR complex according to any one of claims 10 to 17, wherein the T cell receptor is biotinylated at the C-terminus.

19. The TCR complex according to any preceding claim, wherein the T cell receptors are associated with a lipid bilayer.

20 20. The TCR complex according to claim 19, wherein the lipid bilayer forms a vesicle.

21. The TCR complex according to claim 20, wherein the T cell receptors are attached at the exterior of the vesicle.

25 22. The TCR complex according to claim 20 or claim 21, wherein the T cell receptors are attached to the vesicle via derivatised lipid components of the vesicle.

23. The TCR complex according to claim 19 or claim 20, wherein the T cell receptors are embedded in the lipid bilayer.

30 24. The TCR complex according to any one of claims 1 to 18, wherein the T cell receptors are attached to a particle.

25. The TCR complex according to any preceding claim, further comprising a detectable label.

26. The TCR complex according to any preceding claim, further comprising a therapeutic agent such as a cytotoxic agent or an immunostimulating agent.

5 27. The TCR complex according to any preceding claim, in a pharmaceutically acceptable formulation for use *in vivo*.

28. A method for detecting MHC-peptide complexes which method comprises:

10 (i) providing (a) a synthetic multivalent T cell receptor complex comprising a plurality of T cell receptors, and/or (b) a synthetic multivalent T cell receptor complex comprising a multimerised recombinant T cell receptor heterodimer having enhanced binding capability compared to a non-multimeric T cell receptor heterodimer, said T cell receptors being specific for the MHC-peptide complexes;

15 (ii) contacting the multivalent TCR complex with the MHC-peptide complexes; and

(iii) detecting binding of the multivalent TCR complex to the MHC-peptide complexes.

29. The method according to claim 28, wherein the multivalent TCR complex is provided with a detectable label.

20 30. The method according to claim 28 or claim 29, for detecting cells presenting a specific peptide antigen.

31. The method according to any one of claims 28 to 30, wherein the multivalent TCR complex is a multivalent TCR complex according to any one of claims 1 to 27.

25 32. A method for delivering a therapeutic agent to a target cell, which method comprises:

30 (i) providing (a) a synthetic multivalent TCR complex comprising a plurality of T cell receptors, and/or (b) a synthetic multivalent TCR complex comprising a multimerised recombinant T cell receptor heterodimer having enhanced binding capability compared to a non-multimeric T cell receptor heterodimer, said T cell receptors being specific for the MHC-peptide complexes and the multivalent TCR complex having the therapeutic agent associated therewith;

35 (ii) contacting the multivalent TCR complex with potential target cells under conditions to allow attachment of the T cell receptors to the target cell.

33. The method according to claim 32, wherein the multivalent TCR complex is a multivalent TCR complex according to any one of claims 1 to 27.

**ABSTRACT****MULTIVALENT T CELL RECEPTOR COMPLEXES**

The present invention relates to a synthetic multivalent T cell receptor complex for binding to a MHC-peptide complex, which multivalent T cell receptor complex comprises a plurality of T cell receptors specific for the MHC-peptide complex. It is preferred that the T cell receptors are refolded recombinant soluble T cell receptors.

5 The synthetic multivalent T cell receptor complex can be used for delivering therapeutic agents or for detecting MHC-peptide complexes, and methods for  
10 such uses are also provided.